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Abstract 
Cyanobacteria are organisms capable of photosynthesis, and have an important role in 
the ecosystems, since they are involved in nitrogen and carbon cycles. They produce 
secondary metabolites of high diversity including toxins and bioactive compounds. Until 
present, novel compounds were discovered with anti-cancer, antiviral, antifungal, 
antibacterial and antiparasitic potential. The Blue Biotechnology and Ecotoxicology (BBE) 
group at CIIMAR, offers a unique collection of cyanobacteria isolated from water samples 
and solid materials from the Portuguese coast and have conducted studies regarding to 
the bioactive potential of marine cyanobacteria isolated from the Portuguese coast. 
Recent results revealed interesting bioactivities such as cytotoxicity in cancer cell lines, 
bacteria and fungi and toxicity in marine invertebrates. 
In order to respond to the emergent need of natural anti-inflammatory compounds without 
toxic side effects, we performed the present work with the aim to evaluate for the first time 
the anti-inflammatory potential of 13 cyanobacteria strains from the BBE cyanobacteria 
culture collection. The bioactivity of the cyanobacterial fractions was tested in in vitro 
cultures of the mice macrophage RAW 264.7 cell line. The evaluation of anti-inflammatory 
activity was executed by the Griess method.  
The strains Phormidium sp LEGE 06363 and Aphanizomenon sp. LEGE 03283 exerted 
the strongest effects, and were selected for further sub-fractionation using wet chemistry 
extraction techniques as solid phase extraction (SPE) and high pressure liquid 
chromatography (HPLC). After a process of gravity chromatography, the fraction E14026 
A7 of the strain Phormidium sp LEGE 06363 showed anti-inflammatory potential in RAW 
264.7 cells. Unfortunately, the complete isolation of the compound was not possible, since 
the biomass of the subfraction was not enough. The fractions E14035 A2J7, A2J9, A2J10 
and A2J13 from the strain LEGE 03283 demonstrated anti-inflammatory effects, and 
NMR’s analysis was performed to verify the complexity of the compounds. These 
subfractions still contain more than one compound. Consequently, further purification is 
needed in order to isolate the responsible compound for the bioactivity.  
This study represents a first step in the study of the bioactive anti-inflammatory potential 
of cyanobacteria from the BBE collection. Strains with interesting potential were identified, 
but additional methodologies must be performed to finally purify and isolate the 
responsible compound and to decipher their main molecular targets. 
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Resumo 
As cianobactérias são organismos conhecidos por serem capazes de realizar o processo 
fotossintético e possuem um papel importante nos ecossistemas, uma vez que estão 
envolvidas nos ciclos do azoto e carbono. São também responsáveis por produzir 
diversos metabolitos secundários, que adquiriram importância com a recente pesquisa do 
potencial de bioatividade. Atualmente, estudos científicos já permitiram a descoberta de 
novos compostos com forte capacidade anticancerígena, antiviral, antifúngica, 
antibacteriana e antiparasitário. O grupo BBE no CIIMAR, oferece uma coleção única de 
cianobactérias isoladas de amostras de água e de materiais sólidos a partir da costa 
Portuguesa e foram realizados estudos sobre o potencial bioativo de cianobactérias 
marinhas isoladas do litoral Português. Resultados recentes revelaram bioatividades 
interessantes, tais como citotoxicidade em linhas celulares de cancro, bactérias e fungos 
e toxicidade em invertebrados marinhos. 
A fim de responder à necessidade emergente de compostos anti-inflamatórios naturais 
sem ou com menos efeitos secundários que os AINEs, realizou-se o presente trabalho 
com o objetivo de avaliar o potencial anti-inflamatório de 13 espécies de cianobactérias, 
da coleção de culturas de cianobactérias do grupo BBE. A bioatividade das frações das 
cianobactérias foi testada em culturas in vitro da linha celular de macrófagos de ratos 
RAW 264.7. A avaliação da atividade anti-inflamatória foi executada através do método 
de Griess. 
As estirpes Phormidium sp LEGE 06363 e Aphanizomenon sp. LEGE 03283 foram as 
que exerceram efeitos mais fortes e selecionadas para posterior sub-fracionamento 
utilizando técnicas de química de extração como a extração em fase sólida (SPE) e 
cromatografia líquida de alta pressão (HPLC). Depois de um processo de cromatografia, 
por gravidade, a fração E14026 A7 da estirpe Phormidium sp LEGE 06363 mostrou 
potencial anti-inflamatório na linha celular RAW 264.7, embora o isolamento do composto 
não foi possível, uma vez que o peso da fração não era o suficiente. Depois de um 
período de purificação, as frações E14035 A2J7, A2J9, A2J10 e A2J13 de LEGE 03283 
demonstraram efeitos anti-inflamatórios, e foi realizada a análise de NMR para verificar a 
complexidade dos compostos. As frações são ainda complexas, por isso, é preciso um 
outro período de fracionamento e purificação de modo a isolar o composto. 
Longe de este estudo estar completo, representa apenas um primeiro passo no estudo do 
potencial anti-inflamatório bioativo de cianobactérias marinhas. Outras metodologias 
adicionais devem ser realizadas para realmente purificar e isolar o composto que é 
responsável por exercer este efeito e para confirmar os resultados. 
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1. Introduction 
1.1 Innate immune system VS adaptive immune system 
The immune system is constituted by two major subdivisions: the innate or non-specific 
immune system and the adaptive or specific immune system. Both major subdivisions of 
the immune system possess cellular and humoral characteristics by which they carry out 
their protective task. Even though these two arms of the immune system have distinct 
functions, they interact between each other (i.e., components of the innate immune 
system influence the adaptive immune system and vice versa) (Cruvinel et.al., 2010; 
Mayer, 2016). 
Innate immunity represents the first line of defence of a mammalian organism in order to 
respond to a large, however limited number of stimuli. It is represented by physical, 
chemical, and biological barriers, expert cells and soluble molecules, is not specific for an 
antigen or immunogens, and, after contact, it remains the same in quality and quantity. 
This system has defences that are present and ready to be mobilized when an infection is 
realized. Consequently, in the first hours and days after the exposure to new stimuli, we 
trust on our innate immune system to protect us from infection (Mayer, 2016; Alberts 
et.al., 2002; Cruvinel et.al., 2010). 
Adaptive immune system acts like a second line of defence and protects the organism 
against re-exposure to the same offending agent. However, it takes a while to respond for 
the first time when in contact with a new invading organism. Since its initiation depends on 
activation of specialized cells, as specific clones of lymphocytes B and T, this organisms’ 
defence can take a week before the responses turn efficient. This process occurs 
because the adaptive immune system demonstrates immunological memory. It has the 
ability to “remember” the last time it has encountered an offending agent and so it reacts 
more quickly on subsequent exposure to the same organism (Mayer, 2016; Alberts et.al., 
2002; Cruvinel et.al., 2010). 
Acquired response is constituted by the main followed features: self-control, specificity 
and diversity of recognition, immunological memory, expert response and tolerance to 
components of the organism itself. The main cells involved in this kind of defence are 
lymphocytes, still antigen presenting cells (APC’s) play a key role in its activation, offering 
antigens associated with molecules of the major histocompatibility complex (MHC) to T 
lymphocyte (TL) (Mayer, 2016; Alberts et.al., 2002; Cruvinel et.al., 2010). 
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Component/Features Innate immunity Adaptive immunity 
Main differences 
Antigen-independent 
response 
Antigen-dependent 
response 
Not antigen-specific Antigen-specific 
Instantaneous and 
maximal response after 
exposure 
Long time between 
exposure and maximal 
response  
No immunologic memory Immunologic memory 
Cells 
Phagocytes (dendritic 
cells, macrophages, 
and neutrophils) 
Natural killer (NK) 
Mast cells, eosinophils 
and basophils 
NK/T, B, and T 
lymphocytes 
Dendritic cells or APC’s 
Soluble molecules 
Complement 
Acute phase proteins 
Cytokines 
Chemokines 
Antibodies 
Cytokines 
Chemokines 
Table 1: Main differences between innate immune system and adaptive immune system (adapted from Cruvinel et. 
al., 2010 Mayer, 2016) 
 
1.2 Concept of inflammation 
Several diseases and health problems are related to the inflammation of tissues. An 
inflammatory response is a symptom of a lesion or tissue infection recognized by an 
increased vascular permeability and plasma extravasation. This process brings cells and 
molecules, like mediators, leucocytes and an increase of fluid, from the host’s defences to 
the inflammation sites where they are needed to destroy the infective agent (Oliveira 
et.al., 2014; Kumar et.al., 2015; Damte et.al., 2011; Heras et.al., 2009). Generally, 
inflammation suggests a harmful reaction, but it is considered a protective response that is 
essential for human and animal survival. It could have several causes like infections, 
trauma, tissue necrosis, immune responses and foreign bodies (Kumar et.al., 2015). 
Generally, acute and chronic inflammation is distinguished.  
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Chronic vs acute inflammation  
 
 
 
 
 
 
 
 
 
Figure 1: Mechanisms of acute and chronic inflammation and their principal mediators (adapted from Kumar et.al., 
2015) 
 
Acute Inflammation 
Every time a host’s body meets an injurious agent, for example, an infectious microbe or a 
dead cell, components of the cells such as phagocytes try to eliminate these agents, as a 
first defence of the organism (innate immune system). Their goal is to eradicate these 
infectious agents. Acute inflammation is a short-term process that involves a vascular 
response and the recruitment of polymorphonuclear granulocytes, typically neutrophils, 
followed by monocytes, that later, in situ, can differentiate into macrophages. 
 
Major components of Acute 
Inflammation 
Increase in blood flow due to 
vasodilatation 
Increase permeability, leading to 
leukocytes and plasma proteins to leave 
the circulation 
Movement and accumulation of leukocytes 
at the site of infection and their activation 
Table 2: Major components of acute inflammation (Kumar et.al., 2015) 
 
First, phagocytes and other defence cells are responsible to release some mediators of 
the inflammation process, like cytokines, prostanglandines, kinins, lipid messengers, etc. 
This kind of mediators can act on small vessels in the adjacent area, encouraging the 
efflux of plasma and the emigration of leukocytes to the site of injury. Second, the 
leukocytes are activated by the infectious agent and the mediators. Their activation allows 
the elimination of the infectious agent. During this process, the infectious agent is 
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destroyed and the host can be healthy again. In the case of the foreign compound do not 
be fast eliminated, it can develop to a chronic inflammation. 
Some acute inflammation symptoms are redness, warmth and swelling as a response to 
the increased blood flow and edema. The leukocytes present in the blood flow adhere, 
traverse the endothelium and travel to the site of injury, activated by chemotactic agents.  
Once they get activated, they are able to release proteases and toxic metabolites to the 
outside of the cell, which produces tissue damage. Pain is a result of such damage and 
the release of prostaglandins, neuropeptides, and cytokines (Kumar et.al., 2015; Heras 
et.al., 2009; Jo et.al., 2010). 
 
Chronic Inflammation 
Chronic inflammation is a process that can follow acute inflammation or may begin 
insidiously. It is characterized by a reaction of prolonged duration, in which inflammation, 
tissue injury and efforts of repairing coexist, in numerous combinations. 
Chronic inflammation can be derived from different causes, such as: 
a) Persistent infections by microorganisms difficult to eradicate (mycobacteria, virus, 
fungi). 
b) Hypersensitivity diseases, like auto-immune diseases that occur when auto-
antigens evoke a self-perpetuating immune reaction, which results in chronic tissue 
damage and inflammation. This is based in an excessive and inappropriate activation 
of the immune system (asthma, multiple sclerosis, rheumatoid arthritis). 
c) Continued exposure to toxic agents, either exogenous or endogenous; this type of 
inflammation, leads to an in situ activation of numerous cell types such as 
macrophages, plasma cells, lymphocytes, other leukocytes and the respective 
formation of mediators. The dominant cells are macrophages, which have an important 
role, since they contribute to the reaction by secreting mediators such as cytokines and 
growth factors. These mediators behave as intermediates because they act on diverse 
cells, or activate other, especially T lymphocytes, which are able to destroy foreign 
invaders. The inflammatory reaction can be longer or bigger depending on the 
occurrence of a bidirectional interaction between these cells (Kumar et.al., 2015; Jo 
et.al., 2010). 
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Feature Acute Chronic 
Onset Fast (minutes/hours) Slow (days) 
Cellular infiltrate Neutrophils 
Monocytes, macrophages, 
lymphocytes 
Tissue injury, fibrosis 
Commonly mild and self-
limited 
Often severe and 
progressive 
Local and systemic signs Prominent 
Less prominent, can be 
subtle 
Table 3: Features of acute and chronic inflammation (adapted from Kumar et.al., 2015) 
 
Generally, an inflammatory response by an organism involves the release of reactive 
oxygen species (ROS) through activated neutrophils and macrophages (Oliveira et.al., 
2014). 
 
Reactive Oxygen Species  
Reactive Oxygen Species (ROS) is the term that includes several oxygen radical 
compounds and some non-oxidizing radical compounds such as hypochlorous acid, 
hydrogen peroxide, ozone, etc. ROS are compounds, which have a tendency to donate 
oxygen atoms to other substances. Typically, highly reactive ROS possess more volatility 
and one or more unpaired electrons (Kumar, 2011; Ferreira et.al., 1997). All biological 
systems produce ROS (Ferreira et.al., 1997), which can derive from internal or external 
sources, such as: natural metabolic processes or exposure to radiation, air pollutants, 
industrial chemicals, respectively (Kumar, 2011). 
In normal physiological conditions, O2 is reduced, since it accepts four electrons, forming 
the H2O molecule. Throughout this process, some ROS are formed, such as the 
superoxide radical (O2-), hydroperoxyl (HO2.), hydroxyl (OH) and hydrogen peroxide 
(H2O2). In a normal situation, the complete reduction of O2 occurs within the mitochondria 
and the high reactivity of ROS is neutralized with the input of the four electrons (Ferreira 
et.al., 1997).  
Figure 2: ROS formation (www.biospectrum.com) 
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In contrast, oxidative stress occurs when the balance is disturbed between the production 
and destruction of ROS. There must be equilibrium between the reduction and oxidation 
of these compounds, which is determined by the presence of electrons responsible for the 
redox flow pairs. Certain changes in a biological system that influence this balance can 
lead to oxidative stress. The intensity and danger of this processes depends essentially 
on the concentrations of antioxidants and pro-oxidants, the constant reaction rate with 
target molecules and cellular compartmentalization of these processes, which solubility 
and diffusion are essential (Vasconcelos et.al., 2007). 
Cases with inflammation of cells, as noted previously, may lead to excessive production of 
ROS and hence the triggering of oxidative stress process. 
 
Nitric Oxide Production 
Nitric oxide (NO) is a product resulting from the activation of macrophages by cytokines, 
microbial compounds or both. NO is derived from the oxidation of amino acid L-arginine 
by a family of isoenzymes, known as nitric oxide synthases (NOS): nNOS –neuronal nitric 
oxide synthase, iNOS – inducible nitric oxide synthase and eNOS -  endothelial nitric 
oxide synthase and functions as a tumoricidal and antimicrobial molecule in vitro and in 
vivo (Bogdan, 2001; Speranza et.al.,2010; Johann et.al., 2007). NO concept has been 
accepted as explained above, however in the last years the scientific community 
recognized NO essential in the immune system.  
The production of NO is a characteristic of original immune-system cells (NK cells, 
dendritic cells, mast cells and phagocytic cells counting macrophages, Kupffer cells, 
neutrophils, monocytes, microglia and eosinophils), but it is certain that other cells are 
involved in immune feedbacks (endothelial cells, vascular smooth muscle cells, epithelial 
cells, keratinocytes, fibroblasts, chondrocytes, mesangial cells, hepatocytes, and 
Schwann cells) (Bogdan, 2001). 
While cytokines are responsible for the regulation of the expression of iNOS, nNOS and 
eNOS, the activity of some proteins is switched on by the elevation of intracellular 
concentrations of Ca2+ and the binding of the protein calmodulin (CaM), as a response to 
neurotransmitters or vasoactive substances. Even at fundamental Ca2+ levels, this protein 
is strongly connected to iNOS and is distinguished from the constitutive isoforms due its 
prolonged production of a relatively large amount of NO (Bogdan, 2001; Musial & Eissa, 
2001). 
The three isoforms of NOS’s may operate during immune responses in different levels of 
regulation (Bodgan, 2001). Cytokines regulate iNOS by activation of the iNOS gene 
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promoter, which has been analyzed systematically in epithelial cell lines, mouse 
macrophages, and human hepatocytes. In this process, diverse transcription factors are 
involved like NF-κB, AP-1, nuclear factor interleukin-6 (NF-IL-6), the signal transducer and 
activator of transcription (STAT)-1α, interferon regulatory factor-1 (IRF-1), and the high-
mobility group-I(Y) proteins. The signalling pathway involved will be different depending 
on the cytokine or microbial stimulus, and the response to that will promote or inhibit iNOS 
expression. Therefore, there will be different feedbacks depending on the amount of NO 
produced: (i) low concentrations of NO activate NF-κB and make a positive feedback thus 
upregulating iNOS; (ii) high concentrations of NO have the opposite effect, which may 
help prevent NO overproduction (Bodgan, 2001). 
One of the several mechanisms that suppresses the NO production in macrophages, by 
transforming the Growth Factor β (TGF-β) is the increased degradation of iNOS protein. 
The protein degradation is also responsible to control nNOS and iNOS involving the 
proteasome pathway. When in presence of lipopolysaccharide (LPS), the iNOS gene, in 
the macrophages, is stimulated and so, increase the amount of steady-state iNOS protein 
(Musial & Eissa, 2001; Johann et.al., 2007). 
NO is a compound that mediates many physiological functions, as a result, it is the main 
target to investigate in many different pathological conditions. However, NO, per se, has a 
problem regarding its quantification, since it has a short half-life (milliseconds or less, 
depending on the environment) when in the surrounded environment exists O2 and other 
scavenging compounds, for example, haemoglobin (Giustarini et.al., 2008).  
Consequently, many assays measure the presence of NO in an indirect way. Usually, 
some markers are preferred as an index of NO production. On one hand, those that 
accumulate from the stable degradation of NO, nitrite (NO2-) and nitrate (NO3–), S-
nitrosothiols and on the other hand, those, which produce an increase in cGMP levels, 
due to NO dependent initiation of guanylyl cyclase (Tsikas, 2005; Giustarini et.al., 2008). 
The final products of the NO oxidation pathways are nitrite and nitrate and, as a result, 
their concentration in human body fluids depends on NO production itself.  
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Lipopolysaccharides  
 
 
 
 
 
 
 
 
 
Figure 3: LPS composition (adapted from Parija, 2012) 
 
Lipopolysaccharides (LPS) are normally used in bioassays to assess the inflammation 
process. An exposure of at least 4h to LPS induces an inflammation on the cells. The 
macrophages are then activated and start fighting against the LPS presence (Kellog et.al., 
2015; Dey et.al., 2005; Johann et.al., 2007). LPS are complex molecules, also known as 
lipoglycans and endotoxins, present in the external membrane of gram negative bacteria 
(Parija, 2012). Due to their structure and composition, LPS are considered an important 
toxin that protects the cell’s membrane against certain chemical attacks, increases the 
negative charge of the cell’s membrane and helps to stabilize the overall membrane 
structure.  
It is an essential molecule to gram-negative bacteria, since its removal or mutation results 
in bacterial death (Raetz & Whitfield, 2002). Structurally, LPS are divided in three main 
parts: Lipid A, O antigen (or O polysaccharide) and Core oligosaccharide.  
(1) Lipid A:  Consists in a phosphorylated glucosamine disaccharide attached to a 
long chain of fatty acids. This hydrophobic fatty acid chain anchors the LPS into the 
bacteria’s membrane, and the rest of the LPS projects from the cell surface. Lipid A is the 
LPS domain responsible for the toxicity of the LPS when released into the animal’s cells. 
When the immune system attacks the bacterial cells, some fragments of membrane and 
Lipid A are released producing symptoms like fever, diarrhea and septic shock. Variations 
in lipid A structure among different species of gram-negative bacteria are short, remaining 
similar within the same species. 
(2) O antigen: Has different sugars in its composition, depending of the strain. It is 
attached to the core extending outwards, to the surface of the bacterial cell, and as a 
consequence, is the target for recognition by the host antibodies. 
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(3) Core oligosaccharide: Includes two characteristic sugars – KDO and a heptose 
that are attached to the Lipid A. The LPS cores of many bacteria contain non-
carbohydrate components, such as phosphate, amino acids, and ethanolamine 
substitutes (Parija, 2012). 
 
1.3  Anti-inflammatory compounds from synthetic source  
On the one hand, clinicians rely on drugs with the ability of soothe inflammatory processes 
as a consequence of an injury or diseases like rheumatoid arthritis, asthma, 
atherosclerosis, Alzheimer's, among others, which may be considered as recurrent 
excessive inflammation. On the other hand, anti-inflammatory drugs are usually used to 
treat moderate pain such as menstrual pain, headache and muscle pain. The most 
commonly used pharmaceuticals as treatment for inflammation can be non-steroidal and 
steroidal (Oliveira et.al, 2014; Alolga et.al., 2015).  
Non-steroidal anti-inflammatory compounds (NSAID’s) are consumed by humans for the 
treatment of pain, fever and acute or chronic inflammation (Alolga et.al, 2015; 
www.CRBestBuyDrugs.org - Consumer Reports Best Buy Drugs). According to IMS 
Health (Technology company and health information), NSAID's are the most prescribed 
drugs in the USA with more than 98 million prescriptions in 2012 
(www.CRBestBuyDrugs.org - Consumer Reports Best Buy Drugs). These drugs are 
compounds with different chemical molecules and structures and distinct therapeutic 
potential drugs, which have three features in common: (i) basic pharmacological 
properties, (ii) identical basic mechanism of action, as well as (iii) similar adverse effects. 
In addition, all drugs of this group have an acidic character. Most NSAID’s are weak acids 
with pKa values ranging from 3.0 to 5.0 (medium strength acid) (Gouda et.al., 2013). 
These types of compounds are known for containing in its structure hydrophilic (carboxylic 
or phenolic group) and lipophilic groups (aromatic ring, halogen atoms). In the stomach, 
NSAID’s acquire the lipophilic form, since they have acidic characteristics, whereas more 
propitious conditions in the small intestine favour the absorption of weak acids. In the 
plasma, these compounds are found in ionized form. They have a high affinity to plasma 
proteins (> 97%) and therefore aren’t readily distributed in the extra-vascular systems. 
Their metabolism occurs mainly in the liver by oxidation processes and combination of 
inactive metabolites. These are subsequently excreted in the urine or bile (Gouda et.al., 
2013). 
NSAID’s are responsible for blocking the production of substances, which are called 
prostaglandins. These chemicals are derived from fatty acid metabolism via the route 
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COX (cyclooxygenase) and play a role in pain, inflammation, fever, asthma, glaucoma, 
osteoporosis, cancer, cardiovascular disease, birth and male sexual dysfunction 
(www.CRBestBuyDrugs.org - Consumer Reports Best Buy Drugs; Rao & Knaus, 2008). In 
low doses, NSAID's work essentially as pain relievers. In higher doses, these drugs 
reduce the inflammatory response due to tissue damage and relieve the pain associated 
with this inflammation. More specifically, they work by blocking the action of the enzymes 
COX-1 and COX-2, which are involved in the production of prostaglandins. For this, 
NSAID’s mode of action is due to the inhibition of the prostaglandin production by 
inactivating enzymes involved in the process.  
Although the treatment of inflammation is effective with the use of NSAIDs, the risks are 
often higher than the benefits. The prostaglandins produced by COX-1 enzyme may assist 
in the protection of the gastric mucosa and its absence leads to the risk of developing 
severe haemorrhages and ulcers. Moreover, the continued use of these drugs can still 
bring many side effects such as the injury of the gastrointestinal and renal systems, fluid 
and salts retention, heart attacks, strokes, and others (Qandil et.al., 2012; Gouda et.al., 
2013; Rao & Kaus, 2008).  
The NSAID's are divided into the following groups, regarding to their chemical structure: 
derivatives of salicylic acid (such as salicylamide, aspirine, sodium salicylate); aniline and 
derivatives of p-aminophenol (acetaminophen); pyrazolone derivatives (phenylbutazone, 
propyfenazona); oxicams (such as piroxicam, tenoxicam, meloxicam, between others); 
derivatives of the arylalkanoic acids (aceclofenac, diclofenac, indomethacin, between 
others); derivatives of the 2-arylpropionic acids (profens) (such as ibuprofen, flurbiprofen, 
naproxen, ketoprofen, tiaprofenic acid); N-arylanthranilic acids (fenamic acids) (like 
olfenamic acid, mefenamic acid flufenamic); enolic acid and coxibs derivatives (for 
example, rofecoxib, celecoxib, etoricoxib, etc.); naphtylbutanone derivatives 
(nabumetone); sulphonamide (nimesulide); derived benzoxazocine (nefopam). 
 
Age 
Risk of gastro 
intestinalis 
bleeding 
Risk of death 
due to GI’s 
bleeding 
16-44 1 in 2100 1 in 12353 
45-64 1 in 646 1 in 3800 
65-74 1 in 570 1 in 3353 
>75 1 in 110 1 in 647 
Table 4: NSAID’s risks (Adapted from www.CRBestBuyDrugs.org - Consumer Reporters Best Buy Drugs). GI, 
gastro intestinalis bleeding.  
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1.4 Pharmaceuticals from natural source  
Despite the great advances with the synthetic drugs, natural compounds are still 
considered a suitable source for novel and efficient anti-inflammatory drugs, and a high 
percentage maybe used as novel compounds in clinical trials (Costa et.al., 2014). 
It is urgent to find other clinical techniques to treat diseases with symptomatic 
inflammation. Ideally, new and safer compounds will be developed without severe side 
effects as mentioned above. Medicinal plants, seaweed and some species of trees have 
been described as viable alternative sources of natural compounds with anti-inflammatory 
properties. Extracts of a species of tree growing in Mato Grosso, Brazil, Dilodendron 
bipinnatum, was shown to be capable of treating different situations of inflammation 
(Oliveira et.al., 2014). Their mechanism of action involves the inhibition of the migration of 
cells and of mediators of inflammatory response, by inhibiting the Th1 and Th2 cytokine 
stimulation without harming the NO pathway (Oliveira et.al., 2014). Other civilizations, 
such as Japan and China, often turn to brown algae for treatment of hyperthyroidism and 
other diseases associated with glands that are both examples for chronic inflammation 
diseases (Almeida et.al., 2011). 
In recent decades, the scientific community uncovered that algae and marine microalgae 
are one of the richest and most promising natural sources of primary and secondary 
metabolites. This type of organisms produces many compounds, such as carotenoids, 
terpenoids, xanthophyll, chlorophyll, vitamins, polyunsaturated and saturated fatty acids, 
amino acids, acetogenins, antioxidants, such as alkaloids, polyphenols, polysaccharides, 
halogenated compounds. Those compounds can have different bioactivities, e.g. 
antimicrobial, antifouling or UV light protection agents, cancer, AIDS, inflammation, pain, 
arthritis, or viral, bacterial or fungi infections (Almeida et.al., 2011; Deig et.al., 1974). 
Nowadays, algae are the source of about 9% of biomedical compounds obtained from the 
sea (Almeida et.al., 2011; Jha et.al., 2004). Natural products are still an important source 
for drug discovery, either used directly or as template for structural alterations. In 2010, 
approximately 10% of the drugs on the market were unaltered natural products, 29% 
derived from natural products and employed as template for novel compounds, and the 
remaining (61%) were synthetic drugs (Castro et.al., 2016). 
 
1.5 Cyanobacteria 
Phytoplankton or microalgae are photosynthetic organisms that live suspended in the 
water and even though they represent less than 1% of Earth’s biomass, they are primary 
producers and very important since they are in the base of the food web. These 
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organisms can be divided in three main groups: diatoms, dinoflagellates and 
cyanobacteria (Hallegraeff, 2003; Leão et.al., 2011). 
Cyanobacteria are fascinating organisms derived from an ancestral strain of bacteria that 
can be found in different habitats and different varieties. They have a rather important role 
in the ecosystem, since they are involved in carbon and nitrogen cycles. (Morais et.al., 
2015; Dittman et.al., 2015). Cyanobacteria have fossil records from over 2 billion years 
ago and they appear in various aquatic environments, from both salted water to fresh 
water, can have different sizes, colours, and shapes. They are the only bacteria capable 
of oxygenic photosynthesis and their high adaptability to each ecosystem could be the 
reason why they are so prolific in secondary metabolites (Morais et.al., 2015; Miranda 
et.al., 2001). 
Cyanobacteria are a Phylum that belongs to the Bacteria Domain. They have 2 to 40 μm 
in diameter, and have a complex cell wall constituted by a thick peptidoglycan layer and 
periplasmic space between the internal cytoplasmic membrane and the external cell 
membrane. The outer cell membrane consists of lipopolysaccharides, phospholipids and 
proteins, while the intracellular space is composed of proteins, enzymes and metabolites 
(Madigan et.al., 2010). 
Cyanobacteria taxa were determined according to the Botanical Code of Nomenclature 
and include five major groups (Rippka et.al., 1979): 
I (Chroococcales) — unicellular cyanobacteria that divide by binary fission or budding, II 
(Pleurocapsales) —unicellular cyanobacteria that reproduce by multiple fission, III 
(Oscillatoriales) — non- heterocystous filamentous cyanobacteria that split in only one 
plane, IV (Nostocales) — heterocystous and filamentous cyanobacteria that split in only 
one plane, V (Stigonematales) —filamentous heterocystous cyanobacteria that reproduce 
in more than one plane (Boone & Castenholz, 2001). 
 
Bioactive Compounds from Cyanobacteria 
Cyanobacteria are usually known for the formation of toxic blooms in various water 
systems around the world, contributing to the intoxication level of public health, due to the 
release of toxic compounds (Dittman et.al., 2015). However, in the last years, 
investigation has been made to better understand the nature of certain metabolites 
produced by cyanobacteria, with the ultimate goal of finding new substances with 
applications for human health. Many of those cyanobacterial compounds have shown to 
have biological activity relevant to human health (Dittman et.al., 2015). Today, several 
drugs have been developed and obtained from marine natural sources (Singh et.al., 
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2011). 24% of the commercially available natural products for biomedical research are of 
cyanobacterial origin (Gerwick & Moore, 2012). The most famous example of a 
cyanobacterial compounds with biomedical application is Brentuximab vedotin, a synthetic 
compound with origin from a cyanobacterial metabolite, which passed the FDA approval 
for clinical use as anticancer drug (Katz et.al., 2011). 
These bioactive compounds may be obtained directly from the primary metabolism, such 
as proteins, fatty acids, vitamins and pigments or from the secondary metabolism (Dittman 
et.al., 2015; Singh et.al., 2011). 
Since studies from Richard E. Moore in the 70’s, evidence was presented that marine 
cyanobacteria could be an efficient source of secondary metabolites relevant to biological 
activities especially in the fight against cancer and neurotoxicity (Nunnery et.al., 2010). 
Natural products obtained from cyanobacteria can be divided in a diverse range of 
structural classes, including peptides, polypeptides, alkaloids, lipids, and terpenes. Their 
structures can be complex with a range of unusual modification (Dittman et.al., 2015). 
Such compounds may show a broad spectrum of activities, such as antifungal, antiviral, 
anti-enzyme, antibiotic, anti-tumor, anti-bacterial and protease inhibitors (Dittman et.al., 
2015; Singh et.al., 2011). Up to now, more than 800 metabolites have been described 
from various taxa and beyond that, one single strain of cyanobacteria is able to produce a 
wide array of structurally different secondary metabolites. Filamentous marine 
cyanobacteria from subclass III (Oscillatoriales) represent nearly half of the 800 
compounds reported so far (Gerwick et.al., 2008). 
 
 
 
 
 
 
 
 
 
 
Figure 4: Distribution of reported cyanobacterial secondary metabolites through the five major botanical sub-classes (adapted from 
Gerwick et.al., 2008). 
 
The biosynthesis of mixed metabolites originates from an intermingling of genes 
responsible for encoding biosynthetic enzymes, which have the function of linking amino 
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acids and acetate subunits. In most cases, the metabolites resulting from the 
cyanobacteria activity are from a natural arrangement, since it is possible that they can 
appear as combinations of different biosynthetic subunits and under several juxtapositions 
(Nunnery et.al., 2010). 
During evolution, cyanobacteria revealed a bright ability to produce this kind of bioactive 
compounds, which could be related to their need to defend them against predation by 
other organisms (Dale et.al., 1999). An emerging trend exists to find compounds with 
pharmacological capabilities from marine cyanobacteria, in contrast to the past 
perspective, where cyanobacteria were only considered as producer of a range of toxic 
metabolites. To illustrate this, recent studies revealed some natural cyanobacterial 
compounds with anti-inflammatory properties (Villa et.al., 2010). This perspective has 
been revolutionizing the world of cyanobacteria and updates the knowledge we had about 
secondary metabolites from marine cyanobacteria. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Number of compounds extract from cyanobacteria and their bioactivities (Adapted from Dittmann et.al., 2015) 
Anti-Inflammatory Activity  
Many new compounds were discovered after extract fractions with real potential to treat 
diverse diseases, but the focus has, however, been in discovering new drugs for cancer 
treatment. Some of these new molecules were or are still in preclinical and/or clinical 
assays (Gerwick et.al., 2008). In the following, we refer to studies dealing with anti-
inflammatory bioactivity of plants, seaweed and cyanobacteria. 
Plant’ source 
 
A recent study (Iwamoto et.al., 2015) revealed that the species Piper umbellatum, known 
in Brazil as “malvarisco”, is a promising source of natural compounds with anti-
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inflammatory activity and anti-cancer, since it is bioactive both in vitro and in vivo, and has 
no side effects, even at high doses. 
A last year study (Shaikh et.al., 2015) revealed that some species of plants have anti-
inflammatory activity, e.g. Terminalia bellarica, Cissus quadrangularis, Plumbago 
zeylanica, Terminalia chebula. The ethanolic extracts were shown to produce a significant 
decline in the volume of carrageenan induced mice paw edema after 1 hour (32.85% and 
34.28%, respectively) by the oral administration of different doses, e.g. 250 mg/kg of T. 
bellarica and T. chebulla. Indomethacin (20 mg/kg) - standard anti-inflammatory medicine 
- was used as control to compare the results of this investigation, which showed effective 
inhibition (51.48 %) at 5 h. Both medicinal plant species Terminalia (T. bellarica and T. 
chebula) are the major constituents of a popular formulation called ‘Triphala’, prescribed 
by clinical physicians and most of the traditional healthcare practitioners in India and many 
Asian countries.  
Mathew et.al. (2013) showed that ethanolic and aqueous extracts from Kalanchoe Pinnata 
(Lam.) Pers (Family-Crassulaceae) have anti-inflammatory activity. They were tested 
against carrageenan induced paw-edema in rats and compared to the standard drug - 
indomethacin. Both types of extracts had anti-inflammatory activity by reducing the 
volume of paw edema in rats at two different doses, 300 and 600 mg/kg. 
Costus speciosus (Koen ex.Retz.) Sm. (crepe ginger, family Costaceae) is originate from 
Malay Peninsula of Southeast Asia and it is an ornamental plant. This plant is used for the 
treatment of various diseases in the Indian traditional medicine, such as: burning 
sensation on urination, fever, flu, flatulence, leprosy, helminthiasis, skin disorders, 
asthma, hiccough, rheumatism, bronchitis, inflammation and anaemia. The n-hexane–
CHCl3 soluble extract from C. speciosus rhizomes contained a new eudesmane acid, 
specioic acid (8) and more seven known compounds.  Compounds 1–4 showed potent 
anti-inflammatory activity, followed by 7 and 8. These results support the use of this plant 
in traditional treatments of inflammatory conditions (Al-Attas et.al., 2015). 
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Figure 6: Chemical structures of the compounds isolated (1-8) from the extract of C. speciosus (Adapted from Al-
Attas et.al., 2015) 
 
The phytochemicals present in Asian individual spices and herbs already revealed to 
suppress proinflammatory mediator expression. Regarding to Red curry paste, that is a 
Thai dish composed by five to seven herbs and spices, the results were astounding. In 
RAW 264.7 macrophage line, phytochemicals present in the red curry paste ethanolic 
extract significantly decreased the NO’s production through the inhibition of the 
expressions of COX-2, TNF-α, iNOS and IL-6 in a dose-dependent manner. This study 
was able to isolate and identify four flavonoids and three carotenoids that contribute for 
the antioxidant and anti-inflammatory activity (Tuntipopipat et.al., 2011). 
 
Seaweed source 
 
Seaweed were shown to be a source of natural compounds with anti-inflammatory 
activities. Seaweed derived polysaccharides (PS) are the most widely studied group of 
metabolites that are the main part of seaweed walls, and may be involved in recognition 
mechanisms between pathogens and seaweeds. The sulphation of PS leads to a diversity 
of biological properties such as anti-viral, anti-inflammatory, anticoagulant, and anti-
tumoral activities (Jiao et.al., 2011).  The most studied sulphated PS are fucans, which 
are made of a fucose backbone. Fucoidan is the best well known fucan and it was 
primarily isolated from brown algae by Kylin in 1913. These fucose-containing sulphated 
PS principally consist of a backbone of (1 → 3)- and (1 → 4)-linked α -L-fucopyranose 
residues, that may be organized in strectches of (1 → 3)- α -fucan or of alternating α (1 → 
3) and α (1 → 4)-bonded L-fucopyranose residues. The residues of L-fucopyranose can 
be replaced by sulphate on C-2 or C-4. Fucoidan has been examined with carefully in the 
Melissa Gomes Ferreira  2016 
17 
 
last years since it was recognized as having a role in the biology of seaweed and for its 
bioactivity in several organisms (Morya et.al., 2011; Li et.al., 2008; Fitton, 2011). Another 
study demonstrated that fucoidan was responsible to inhibit strongly the excessive 
production of PGE2 and NO in LPS-stimulated BV2 microglia (Park et.al., 2011). This 
compound is capable of attenuate the expression of enzymes involved in the inflammation 
process such as monocyte chemoattractant protein-1 (MCP 1), iNOS and COX-2 and pro-
inflammatory cytokines, as IL-1β and TNF-α. MCP-1 is a pro-inflammatory chemokine that 
promotes monocyte recruitment into an inflammatory site; once activated, the recruited 
cells may produce more pro-inflammatory mediators, inducing the inflammation process 
(Park et.al., 2011). Fucoidans are still unexploited as a source of medicines due to their 
heterogenicity and plant source, regardless of their notable bioactivity and no reported 
oral toxicity. There are several experimental studies using Fucus vesiculosus, a vulgar 
harvest crop of a northern hemisphere kelp, as a source of fucoidan (Souza et.al., 2006). 
Sacran is another example of anti-inflammatory sulphated PS derived from marine algae, 
and was extracted from Aphanothece sacrum (an edible blue-green microalga that grows 
in a river in the Kyushu region, Japan). Sacran exerts anti-inflammatory effect on 2,4,6-
trinitrochorobenzene-induced allergic dermatitis in mice, in vivo, once it improves the skin 
barrier function and diminish cytokine production (Ngatu et.al., 2012). Sacran was 
responsible to diminished the scratching behaviour and inhibited the development of 
allergic dermatitis skin lesions. In addition, sacran efficiently inhibited IFN- γ, TNF-α, IL-4, 
IL-5 expression and the infiltration of eosinophiles in allergen-exposed ear skin. 
A study performed in vivo and in vitro mice macrophage demonstrated that the extract 
from the marine alga Gracilaria verrucosa had an increasing effect on innate immunity by 
both oral and intraperitoneal administration. Does mean that compounds present in this 
alga can improve host defense activity against tumors and infection, and that can be 
beneficial for supplements in food with immunopotentiating activity for humans and 
domestic animals (Yoshizawa et.al.,1996). 
In the last decades, in Europe, the consumption of algae has increased since 15 to 20 
different species have been commercialized in France, Greece and Italy. In some western 
countries like Venezuela, USA and Canada, the macroalgae are used in industry as a 
source of hydrocolloids agar, carrageenan and alginate (Almeida et.al., 2011).  
Cyanobacteria source 
Considering anti-inflammatory activity, few studies were published from cyanobacteria 
sources. However, a study from 1984 showed that marine life forms possessed anti-
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inflammatory activity, such as anti-inflammatory compounds from the cyanobacterium 
Rivularia sp. (Baker, 1984). More recently, a study was carried out using the inhibition of 
NO on a mouse macrophage cell line (RAW 264.7) as target, in order to find new 
metabolites from marine cyanobacteria. In this study, the authors concluded that many 
malyngamides, especially of the F series, had a high inhibiting capacity, and thus, an anti-
inflammatory activity. Various concentrations of malyngamide F acetate were analysed for 
its effect on NO production in RAW 264.7 cell line after LPS stimulation to determine its 
dose–response characteristics and potency. The assays revealed an IC50 of 3.4 μg/ml (7.1 
μM) and showed that NO production was significantly inhibited in a concentration-
dependent manner. Malyngamide F acetate is the compound of these secondary 
metabolites that did not reveal cytotoxicity, but had more efficient NO inhibitory activity. 
TNF-α was up-regulated by the treatment with malyngamide F acetate, almost 2fold 
compared to the LPS. TNF- α transcription increase, in contrast to the decrease in the 
cytokines IL-1β, IL-6, and IL-10 transcription, what suggests that malyngamide F acetate 
may be acting upon the MyD88-dependent inflammatory pathway, because usually LPS 
leads to a higher TNF-α transcription and decreases IL-1β in the MyD88 knockout mouse 
by means of the MyD88-independent pathway (TRIF-dependent). To find out more about 
the interactions between MyD88-dependent and -independent pathways, in this work, the 
authors, analysed the transcription of IL-10 and TNF-α in CpG and Poly I:C treated cells. 
Cytokines, included TNF-α were inhibited by the CpG activation of TLR9. Also, Poly I:C 
treatment, which activates TLR3 via a MyD88-independent pathway, with and without 
malyngamide F acetate application did not showed significantly differences in the 
transcription of IL-10 and TNF-α. That means malyngamide F acetate acts by selectively 
inhibate the MyD88-dependent pathway (Villa et.al., 2010 (b)). 
Silambarasan et.al. (2011) analyzed the anti-inflammatory potential of the aqueous extract 
of Trichodesmium erythraeum – a marine cyanobacterial species, found in tropical and 
subtropical areas. This study used albino wistar rats as model system in vivo and the 
inflammation was induced by the administration of carrageenan. After 30 minutes within 
the treatment with extracts from Trichodesmium erythraeum, the inhibition of paw edema 
in the rats was of 57.5 ± 5.5 % to the high dose (500 mg/Kg) and 47.5 ± 4.7% to the 
lowest dosage (300 mg/kg). 
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Figure 7: Different structures of the malyngamides extract from Lyngbya majuscula. These compounds are 
secondary metabolites which combine fatty acyl chains with polyketide synthase extended amino acid subunits 
(Adapted from Villa et.al., 2010 (b)) 
 
1.6  Model Systems 
In scientific investigation and molecular biology, cell culture has an important role as a 
tool. Cell culture is used to study toxicity assays, cancer research, virology, genetic 
engineering, gene therapy, cell-based manufacture, drug screening or development. In 
the last 20 years, macrophage cells (MP) entered into the focus of several laboratories, 
since they revealed a special role in immune regulation and tumor immunity. Macrophage 
cell lines can be obtained in many different ways: (i) from tumours or tumour-like cells; (ii) 
by culturing bone marrow cells using a factor agent that stimulate the macrophage colony- 
and continuing the continuously split of MP’s; (iii) hybridomas are obtained by the fusion of 
diverse kinds of immortalized cells with normal macrophages. The use of MP lines offers 
many advantages: guarantee a homogeneous population and a large number of cells. It is 
also important to refer that the development of in vitro systems to replace animal use in 
science satisfies the controversy and criticism from animal rights groups (Chapes et.al., 
1988).  
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Macrophages 
Today, many kinds of macrophage cell lines are available for scientific studies: (i) RAW 
264.7 is a murine macrophage cell line; (ii) P388D1 is a derivative of P388 selected for the 
high production of IL-1. The cells showed a high reactivity in cell-mediated cytotoxicity 
antibody dependent. (iii) J774.A1 is derived from a tumor in a female BALB/c mouse that 
produces IL-5 and lysozyme. (iii) TPH1 is a human macrophage cell line 
(http://www.lgcstandards-atcc.org). 
RAW 264.7 cell line (mouse monocyte macrophages) is a secondary cell culture derived 
from an induced tumour made by an intraperitoneal injection of Abselon Leukaemia Virus 
(A-MuLV) in a male mouse by and growing attached in a plastic flask or dish. Cells will 
pinocytose neutral red and phagocytose zymosan. This cell line is immortal, since they 
can divide several times from a “mother cell” (http://www.ecacc.org.uk). Stimulation of 
RAW 264.7 can be achieved through LPS endotoxin from gram negative bacteria. Once 
activated, MP’s play a critical role in inflammatory response and secrete nitrogen 
mediators and pro-inflammatory cytokines such as IL-1, IL-6 or TNF-α. This cell line is a 
good model system to study inflammatory processes and to evaluate the effects of 
adenosine receptor ligands as pro- or anti-inflammatory drugs. 
 
Microglia cells 
  
Microglia are innate immune cells of the brain and the local phagocytes. These cells have 
been recognized due to their broad role in the brain’s innate immunity, inflammatory 
disorders of central nervous system (CNS) and homeostasis (Henn et.al., 2009, Stansley 
et.al., 2012). The colonization of CNS by microglia takes place during embryonic 
development in rodents, at a prenatal stage (Stansley et.al., 2012). These cells have a 
similar activation’s behaviour to macrophages and exhibit great functional plasticity when 
activated. They are a good model system to study inflammation diseases in the brain, like 
Alzheimer and Parkinson, and most frequently used are primary microglia and BV-2 or N9 
cells (Henn et.al., 2009, Stansley et.al., 2012). 
Primary microglia (PM) cells are used recurrently in scientific research in neuro-
inflammatory studies, due to the similarities in phenotype to in vivo cells. These cells 
derived from the cortex of a rat or mouse before or early after birth (Stansley et.al., 2012). 
The functional characteristics of these cells, like cell surface markers and secretory 
products are one of the advantages to use PM cells directly from the animal. These cells 
react really well to LPS-stimulation, by producing NO, prostaglandin E2 (PGE2), ROS, 
pro-inflammatory cytokines (TNF-α, IL-6 and IL-1) and MCP-1 (Stansley et.al., 2012, Park 
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et.al., 2011). Their ability to proliferate is quite limited, so they need to be isolated freshly 
for each experiment and it is necessary 15-30 brains of rodents to produce microglia cells 
for a limited amount of experiments on signalling or disease mechanisms. In the 
biomedical research, significantly higher numbers are required, which has a huge impact 
on overall numbers of animal use. An alternative cell line could be better appropriate, 
once it would save time, animals and valued consumables, and facilitate research work. 
The process in this cell line is great to analyse cell markers and enzymes, however 
sometimes the time for preparation it is too much elevated, making this model less 
attractive than others (Henn et.al., 2009, Stansley et.al., 2012). 
BV-2 cells come from raf/myc-immortalised murine neonatal microglia and are often used 
as a substitute for primary microglia. In the process of development of this line, microglia 
were purified by agitation, incubated overnight with control or J2 retrovirus containing 
supernatants in cell specific complete medium. They were incubated for about 3-4 weeks, 
and proliferating cells were observed in infected cultures, where non-infected cultures lost 
adherence and died (Stansley et.al., 2012). BV-2, stimulated by bacterial surface 
molecules (LPS), can indeed trigger activation in astrocytes as assessed by translocation 
of the transcription factor NF-κB and secretion of the cytokine IL-6 (Stansley et.al., 2012). 
Henn et.al. (2009) examined the BV-2 cells as an appropriate alternative to the primary 
cultures. In this study, when in presence of LPS, almost the same genes (90%) induced 
by the BV-2 cells were also induced by primary microglia; however, the up-regulation of 
genes in the BV-2 was far less pronounced than in primary microglia, leading to a less NO 
production comparing to PM, but still in considerable amounts. The BV-2 cell line allows 
technical viability between the procedures and an efficient preparation time (Stansley 
et.al., 2012). BV-2 cells are essential to inflammation studies, since microglia have an 
important role, not only in inflammation process, but also in toxicity conditions, especially 
in neurotoxicity. 
 
Zebrafish  
 
Another different method to evaluate the anti-inflammatory potential of an unknown 
compound is through the zebrafish (Danio rerio). This species is a tropical freshwater fish 
include in the family (Cyprinidae) of the order Cypriniformes. It is a popular fish for 
aquarium and it is native to the Himalayan region. Zebrafish are similar with mammals, 
including humans, since they share their functional homology and have analogous genetic 
sequence (Dahm, 2006). The reproduction is an advantage since it can generate a high 
number of offspring really quickly. Its embryos are robust, large, and translucent, and able 
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to develop in the outer environment (Spence et.al., 2007; Dahm, 2006) However, 
zebrafish are not a collectively ideal research model. Associated to them exist some 
disadvantages to their scientific use, as for example the absence of a standard diet 
(Penglase et.al., 2012) and the presence of some important differences relative to the role 
of some genes involved in human disorders. 
Zebrafish larvae are quite small and are easy to manipulate and observe and also the 
ability of the compounds be pooled to the water bath and immediately absorbed when 
administered in a <1% DMSO solution, therefore, can be used as model system for 
inflammation studies. Wittmann et.al. (2012) proposed a new methodology to execute 
screening of small molecules with the aim of identifying immune modulatory compounds. 
The used larvae have a singular combination of presenting the property of transgenic lines 
expressing fluorescent proteins in leukocytes and the advantage of being optically clear. 
This combination allows the measurement in vivo of an acute inflammatory process 
(Wittmann et.al., 2012). 
 
Humanized mice 
 
A humanized mouse is a mouse that it is able to carry functional human genes, cells, 
tissues, and/or organs. These mice usually are used as mammalian models, for human 
therapeutics in biological and medical research. Because they do not have host immunity, 
they are used as a recipient to human cells, since they can easily accept heterologous 
cells. The process begins when the scientist injects human hematopoietic stem cells (hu-
CD34+) on female mice. Twelve weeks after the procedure, the engraftment of mature 
human white blood cells (hCD45+) is confirmed and considered successfully humanized. 
Humanized mice are a great model system, for long-term in vivo studies and to analysing 
the effectiveness and safety of potential novel drugs to modulate immune system (Brehm 
et.al., 2014, Peltz, 2013; www.jax.org) 
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2. Objectives 
Studies performed earlier at the Blue Biotechnology and Ecotoxicology Group (BBE) of 
CIIMAR had already established that some cyanobacterial strains are producers of 
cyanotoxins and secondary metabolites with interesting bioactivities towards human 
diseases (Martins et.al., 2005). Anti-inflammatory activities of cyanobacterial strains from 
the cyanobacterial culture collection of CIIMAR (LEGE CC, 
http://www.ciimar.up.pt/legecc/) were not studied yet.  
Therefore, the work presented in this thesis has as main objective to analyse the potential 
of cyanobacterial strains to produce anti-inflammatory compounds, which could be used in 
the future for the treatment of inflammatory diseases. The following specific objectives 
were defined: 
 Growth of cyanobacterial biomass  
 Production of extracts and fractions from different species of cyanobacteria 
 Setup of assay conditions for the screening of anti-inflammatory activity 
 Test extracts and fractions in vitro for their anti-inflammatory bioactivity  
 Follow a bioassay-guided isolation process to purify a novel compound of cyanobacterial 
origin with anti-inflammatory activity. 
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3. Material and Methods 
3.1 Culture of cyanobacteria strains 
The Blue Biotechnology and Ecotoxicology Group of CIIMAR has a large collection of 
cyanobacterial strains, isolated from water samples and solid materials from the 
Portuguese coast and freshwater ecosystems (LEGE CC, 
http://www.ciimar.up.pt/legecc/). Culturing of cyanobacteria strains was performed in order 
to obtain a high quantity of total biomass. Cyanobacteria were grown in Z8 medium (25 
g/L) (Kotai, 1972) and maintained at constant temperature of 25ºC with a light intensity of 
approximately 30 μmol photons m-2 s-1 and a light/dark cycle of 14:10h. 
 
 
 
 
 
 
 
 
 
 
  
 
 
3.2 Collection of the biomass  
The collection of biomass of the 3 different strains LEGE 06144, LEGE 06148 and LEGE 
11427 was executed using the methods of centrifugation or filtration depending of the type 
of strain. During this work biomass of those strains was collected, but not used in these 
analyses due to the long phase of growth to have sufficient biomass for bioassay-guided 
fractionation and structure elucidation. So, in this work the strains used in vitro assays 
were cultured and extracted in a previous research project (MARBIOTECH). 
Also, the collected cyanobacterial biomass (MARBIOTECH) followed the standard 
procedure of the BBE group in CIIMAR, and so it was submitted to a normal phase 
vacuum liquid chromatography which resulted in 9 - 11 fractions 
3.3 Cell culture of RAW 264.7  
The murine RAW 264.7 macrophage cell line was used to study the anti-inflammatory 
bioactivity of cyanobacterial compounds in vitro (European Collection of Authenticated 
Figure 8: 6L flask LEGE 06144 
strain 
Figure 9: 10L flask LEGE 
06148 strain 
Figure 10: 10L flask LEGE 
11427 strain 
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Cell Cultures (ECACC), supplied by Sigma-Aldrich). Cells were cultured in DMEM 
Glutamax medium (Dulbecco’s modified Eagle Medium GlutaMAX™) from Life 
Technologies (Thermo Fisher Scientific, Waltham, Massachusetts, USA), supplemented 
with 10% (v/v) fetal bovine serum (FBS, Gibco-Invitrogen), 1% (v/v) of penicillin-
streptomycin (Pen-Strep 1000 IU mL-1) (Life Technologies) and 0.1 % (v/v) of 
amphotericin B (250 μg/mL) (Life Technologies). Cells were maintained in a humidified 
atmosphere with 5% of CO2 at 37ºC in an incubator 8000 DH (Thermo Scientific, 
Waltham, MA, United States of America). Cells were cultured in petri dishes (Orange 
Scientific), and three times a week (Monday, Wednesday, Friday) the culture was 
passaged and split into new Petri dishes. The detachment of the cells was executed only 
with a micropipette, through a process of “up and down” until all the cells were detached, 
since cells have semi-adherent properties. Cells were centrifuged at 1600 rpm for 10 
minutes to form a pellet. Cell density was calculated using the Countess™ Automated Cell 
Counter (Thermo Fisher Scientific) with 10 μL of medium of suspended cells mixed with 
10 μL of trypan blue. Cell density for seeding was 1.3x105 cells/cm2. From time to time, 
some aliquots were frozen at -80˚C in medium supplemented with 10% of FBS and 5% of 
DMSO.  
 
 
 
 
 
 
 
 
Figure 11: RAW 264.7 cell line cultured in petri dishes with complete DMEM (Picture of 25.04.2016, P3) 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: RAW 264.7 macrophage cell line under the microscope  
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3.3.1 Griess reaction for anti-inflammatory bioactivity 
Once the immune system is activated, the production of nitric oxide - NO - occurs 
massively in cells, such as macrophages and mast cells. For this reason, the levels of NO 
are used as markers to detect inflammation by the Griess reaction, a simple and 
commonly applied technique (Miranda et.al., 2001). 
 
 
 
 
 
 
 
 
Fig 13: NO production during the cell inflammation (adapted from Miranda et.al., 2001) 
 
Reagents: 
• N- (1- naphthyl) ethylenediamine dihydrochloride (NEDD) 
• Sulfanilamide (SULF) 
• Sodium nitrite 
• Phosphoric acid (H3PO4) 
• Ultra-pure water 
• NG -monomethyl -L-arginine 
• Lipopolysaccharide (LPS) 
 
Preparation of Griess solutions: 
a) SULF solution was prepared using ultra-pure H2O at 1% (w/v), or 0.1 g / 10 ml. For 
more effective dissolution, the solution was warmed in the water bath at 35ºC and 
sonicated by ultrasounds. 
b) A solution of 5 % H3PO4 was prepared from 85% stock solution by adding 1 ml to 16 ml 
of H2O ultrapure.  
c) NEDD solution was prepared at 0.1 % (w/v), with 0.01 g / 10 ml solution in 5% H3PO4. 
Note: Each solution must be filtered to remove particles. 
Preparation of standard solution: 
a) Sodium nitrite at 1 mM was used as standard in the assay. The solution was prepared 
by dissolving 0.0069 g in incomplete DMEM medium followed by magnetic stirring. This 
solution must be prepared freshly and can be stored in aliquots at -20° C. 
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b) In a 96-well microplate, a dilution series of 1: 2 is made using 1 mM sodium nitrite 
diluted in incomplete DMEM. Complete DMEM medium (as in cell culture) is used as a 
control in triplicates. 
c) The 1st well is filled with 200 µL of sodium nitrite solution. All the remaining wells are 
filled with 100 µL of incomplete DMEM. Afterward, 100 µL of the 1st well are removed and 
placed into the second well, making “up and down” about 5 times before refilling the tip 
and moving to the next well. The same procedure is repeated to the following wells until 
no more wells are available. 
d) The last 100 µL are discarded along with the tip. 
e) Finally 100 µL of the Griess solutions have to be added and the plates incubated in the 
dark for 10 minutes. 
g) The plate is analyzed by spectrophotometry at 540 nm. 
 
Induction of inflammation in RAW 264.7 cells: 
a) This procedure is done in a 24 well microplate seeded with 500 µL RAW 264.7 cells 
at a density of 1x105 cells/cm2. Cells were allowed to attach and grow for 24h. In this 
example, four treatment groups are seeded in triplicates (see Figure below). 
 
 
 
 
 
 
 
 
 
Preparation of stock solution of LPS (L4391 - 1mg – SIGMA; Escherichia coli 
0111:B4) to induce inflammation: 
a) Dilute 1 mg of LPS in 1 ml of incomplete DMEM (concentration of stock 1 mg/ml) and 
store in aliquots of 10 µLin Eppendorfs at -20 ° C.  
b) The stock is diluted 1:1000 dilution in order to get a working solution with a final 
concentration of 1 µg/ml. Each time, 14 µL of the stock solution were diluted in 14 ml of 
Control 100 ng/ml 
LP 
50 ng/ml 
LP 
25 ng/ml 
LP 
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complete DMEM and vortexed for about 1 minute. Then 500 µl was transferred into each 
well of a 24-well microplate, where cells were seeded 24 hours before. 
c) After 24 hours of incubation the exposure is carried out with the Griess test solutions. In 
order to do so, 100 µL of the medium in this plate are removed and placed in 96-well 
microplate; 
d) 100 µL of Griess mixture is added to each well in a ratio of 1: 1 and allowed to incubate 
for 10 minutes in the dark; 
e) After the incubation the samples are read in the spectrophotometer at 540 nm; 
 
Preparation of NMMA solution (M7033-5MG - SIGMA): 
a) NMMA will serve as a positive control in assays, since it is an inhibitor of NO 
production; 
b) Prepare a NMMA solution at 10 mM concentration diluting 0.000248 g NMMA in 10 ml 
H2O or incomplete DMEM. 
d) NMMA solution is diluted 100x to get a concentration of 100 µM. 
e) This solution is added during the treatment with LPS (final concentration of 1 µM in the 
medium) to verify that actually reduces NO levels, as expected. 
f) The remaining solution should be stored in tightly sealed aliquots at -20 ° C for 1 month 
without degrading. If used again, it should be allowed to warm up at room temperature for 
1 hour. 
3.4 Screening of different extracts 
In this work, 13 distinct strains of cyanobacteria from the BEE collection (Fig. 14-17) were 
recovered and 117 different fractions tested for their bioactivity. Fractions were tested in 
RAW 264.7 cells for testing anti-inflammatory activity. The Table 5 gives an overview 
about the tested strains. After the incubation of the cells for 24 hours, LPS was used at a 
concentration of 1 µg/ml to induce inflammation, followed by the exposure to the extracts 
and respective fractions. The fractions were prepared in DMSO with a final concentration 
of 10 mg/ml. In each well of a 24-well microplate, 1.5 µl were added of each fraction (final 
concentration of 30 µg/mL). The solvent control contained 0.3% DMSO. The Figure 18 
shows an example of an exposure in a 24-well microplate. 
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Figure 14: Microscopy’s view of cyanobacteria strains. 1: LEGE 00237; 2: LEGE 03283; 3: LEGE 06071; 4: LEGE 
06077 (From BBE collection) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Microscopy’s view of cyanobacteria strains. 5: LEGE 0679; 6: LEGE 06363; 7: LEGE 07075; 8: LEGE 
07084 (From BBE collection) 
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Figure 16: Microscopy’s view of cyanobacteria strains. 9: LEGE 07175; 10: LEGE 07211; 11: LEGE 07212; 12: LEGE 
91094 (From BBE collection) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Microscopy’s view of cyanobacteria strain LEGE XX280 (From BBE collection) 
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Cyanobacterial strain 
Strain 
(LEGE) 
Extract Fractions (10 mg/ml) Total 
Synechocystis sp. 07211 14031 A-I 9 
Limnothrix sp. 07212 14067 A-J 10 
Oscillatoria limnetica 00237 14032 A-J 10 
Planktothrix planctonica XX280 14028 A-I 9 
Aphanizomenon sp. 03283 14035 A,B,D,E,G,I,J 7 
Phormidium sp. 06363 14026 A,C,D,E,F,G,H,I,J,K 10 
Leptolyngbya sp.  07075 15093 A-I 9 
 Synechocystis sp. 06079  13003 A,C,D,E,F,G,H 7 
 Microcystis aeruginosa 91094  13004 A,B,D,E,F,G,H,I 8 
 Nodularia sp. (aff. 
Sphaerocarpa/harveyana) 
06071 13005 A-I 9 
  Leptolyngbya sp.  07084  13008 A-I 9 
Nostoc sp.  06077 13013 A-J 10 
 Cyanobium sp. 07175 16112 A-J 10 
Table 5: Cyanobacteria strains and respective fractions that were tested in the biological assays  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Example of the exposure of an extract and respective fractions 
 
After 24 hours of incubation, the samples were subjected to the process described in 3.3.1 
and NO levels in supernatant were quantified. The amounts of NO produced for each 
treatment were obtained by reading the absorbance in a spectrometer with the 
wavelength of 540 nm, and by extrapolating to values from a calibration curve using a 
gradient of concentration of sodium nitrite. The NO values were obtained through the 
equation of the calibration curve, in Y = mx + b.  
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3.5 Column chromatography (by gravity) of E14026 A 
After the biological assays, the fraction E14026 A revealed potential bioactivity, and was 
subjected to a column chromatography (silica gel 60, 0.0015-0.040 mm), Merck, KgaA, 
Damstadt, Germany) (Figure 19). This fraction had a weight of 69.5 mg. As this fraction is 
the most polar of all fractions, the silica column was prepared with 100% of hexane. 
Fraction E14026 A was resuspended in EtOAc in ethyl acetate with the help of 
ultrasounds, and loaded on top of the silica column. The gradient of solvents was added 
stepwise, according to Table 6. Through this process, 72 samples were collected in 10 ml 
tubes. Thin layer chromatography (TLC) (silica 60 F254 (Merck)) was performed to 
visualize samples under UV light in order to assess the efficiency of the chromatography 
and to extrapolate the composition of each mixture, as elucidated in Figure 20. Due to 
similar composition, (from the TLC analysis), some samples in elution tubes were pooled 
as depicted in Table 7. In that way, 8 sub-fractions were obtained (1-8) and evaporated in 
RB flasks. The sub-fractions were dried in a rotary evaporator, re-suspended, transferred 
to pre-weighed vials, dried and weighed (see Figure 21). The obtained fractions were 
subsequently tested in the biological assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Column chromatography of the fraction LEGE 06363 - E14026 A 
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Figure 20: TLC of the samples collected during the chromatography process of E14026 A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Rotary evaporator for dry the samples and fractions obtained after chromatography 
 
5% EtOAc 95% Hexane 
6% EtOAc 94% Hexane 
8% EtOAc 92% Hexane 
10% EtOAc 90% Hexane 
12% EtOAc 88% Hexane 
15% EtOAc 85% Hexane 
20% EtOAc 80% Hexane 
100% EtOAc ----- 
9% Methanol 91% EtOAc 
 
Sub-
Fraction 
Tubes (10 mL) RB Flasks 
E14026 A1 1 - 9 500 mL 
E14026 A2 10 - 12 100 mL 
E14026 A3 13 - 14 100 mL 
E14026 A4 15 - 20 200 mL 
E14026 A5 21 - 44 500 mL 
E14026 A6 45 - 67 500 mL 
E14026 A7 68 - 70 100 mL 
E14026 A8 72 + erlenmeyer 200 mL 
Table 6: Gradient of solvents in chromatography Table 7: 8 sub-fractions obtained after the TLC 
 
3.6 Flash Chromatography – Solid Phase Extraction (SPE) of E14035 A 
Fraction A from the extract E14035 revealed strong activity in the biological assays. So 
with a weigh of 173.8 mg, it was decided to perform a flash chromatography using SPE. 
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The column was a normal phase column SPE (Si-20g, Strata, Phenomenex) and silica 
column was compacted with 100% Hexane. The fraction A was resuspended in 10% Ethyl 
Acetate (EtOAc) and 90% Hexane and loaded in the silica column. The mixtures of 
solvents were carefully added stepwise, according to Table 8 and 53 samples were 
collected in 10 mL tubes. Thin layer chromatography (TLC) (silica 60 F254 (Merck)) was 
performed for every eluate and visualized under UV light in order to assess the efficiency 
of the chromatography and to extrapolate the composition of each mixture, as elucidated 
in Figure 23. Some samples were pooled due to assumed similar composition as 
elucidated in Table 9. Sub-fractions were established and evaporated in RB flasks. These 
mixtures were dried in a rotary evaporator, resuspended, transferred to pre-weighed vials, 
dried and weighed before tested in biological assays. 
 
0% EtOAc 100% Hexane 
1% EtOAc 99% Hexane 
2% EtOAc 98%Hexane 
4% EtOAc 96% Hexane 
6% EtOAc 94% Hexane 
8% EtOAc 92% Hexane 
10% EtOAc 90% Hexane 
20% EtOAc 80% Hexane 
40% EtOAc 60% Hexane 
100% EtOAc ----- 
0.1% TFA 99,9% EtOAc 
 
 
Sub-
Fraction 
Tubes (10 mL) RB Flasks 
E14035 A1 1 - 11 500 mL 
E14035 A2 12 - 21 500 mL 
E14035 A3 22 - 25 100 mL 
E14035 A4 26 - 27 100 mL 
E14035 A5 28 - 29 100 mL 
E14035 A6 30 - 34 200 mL 
E14035 A7 35 - 39 200 mL 
E14035 A8 40 - 53 500 mL 
Table 8: Gradient of solvents in chromatography Table 9: 8 sub-fractions obtained after the TLC 
 
 
 
 
 
 
 
 
 
 
Figure 22: SPE chromatography of E14035 A 
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Figure 23: TLC of the sub-fractions of E14035 A collected during the chromatography process 
 
3.7 Semi-preparative normal-phase High Performance Liquid 
Chromatography of E14035 A2 
After the biological assays, sub-fraction A2 was selected for further purification using the 
semi-preparative HPLC, a 1525 Binary HPLC pump and a UV-Vis detector (Waters, 
Milford, MA, USA). This process requires an optimization before the chromatography and 
therefore it is used a Luna 5u Silica (2) column (250 x 4.6 mm, 100 A, Phemomenex) in 
order to assure maximum possible separation of compounds. The Table 10 shows the 
selected conditions, following a gradient of solvents, after the optimization process. 
Previously, the fraction E14035 A2 was resuspended in a mixture of chloroform and 
hexane. The obtained spectrum - the chromatogram - allowed us to collect the 
compounds, according to the observed peaks, in RB flasks from multiple injections of 500 
µl each before evaporation in the rotary evaporator. Sub-fractions were re-suspended, 
transferred to pre-weighed vials, dried and weigh. Finally, we obtained 11 new sub-
fractions. These 11 fractions were tested in the bioassay to evaluate anti-inflammatory 
properties, before 1H NMR (400 MHz, BrukerAvance III) analysis. 
 
 
Table 10: Mobile phase gradient used for the semi-
preparative HPLC on sub-fraction E14035 A2 
Time 
(min) 
Flow 
(mL/min) 
EtOAc Hexane 
0 3 0% 100% 
28 3 20% 80% 
33 3 50% 50% 
40 3 50% 50% 
43 3 0% 100% 
48 3 0% 100% 
 
Table 11: Weight of sub-fractions of E14035 A2 after 
HPLC 
Extract Sub-Fraction Weight (mg) 
E14035 
A2 A 0.83 
A2 B 2.17 
A2 C 1.13 
A2 D 1.3 
A2 E 0.66 
A2 F 0.4 
A2 G 0.77 
A2 H 1.23 
A2 I 2.56 
A2 J 8 
A2 K 1.95 
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3.8 Semi-preparative normal-phase High Performance Liquid 
Chromatography of E14035 A2 J 
After the biological assays and regarding to the weight of each sub-fraction and the results 
of 1H NMR, the fraction E14035 A2 J was chosen for further purification. In this case, it 
was utilized an analytical column - Luna 5u Silica (2) 250 x 4.6 mm, 100 A to optimize the 
procedure and to separate the compounds. The Table 12 shows the selected conditions, 
following a gradient of solvents, after the optimization process. For this sample, the 
optimization took some time, since it was necessary to try different percentages of the 
solvents and different gradients to perform the best separation. Previously, the fraction 
E14035 A2 J was re-suspended in a mixture of ethyl acetate and hexane. The obtained 
spectrum - the chromatogram - allowed us to collect the compounds, according to the 
observed peaks, in RB flasks from multiple injections with 100 µl each one and then 
evaporated in the rotary evaporator. Sub-fractions were re-suspended, transferred to pre-
weighed vial, dried and weighted. Finally, we obtained 13 new sub-fractions. These 13 
fractions were tested in the bioassay to evaluate anti-inflammatory properties, before 1H 
NMR (400 MHz, BrukerAvance III) and LC-MS analysis. 
 
 
Time (min) Flow (mL/min) EtOAc Hexane 
0 1 5% 95% 
8 1 5% 95% 
50 1 40% 60% 
55 1 60% 40% 
60 1 60% 40% 
65 1 5% 95% 
70 1 5% 95% 
Table 12: Mobile phase gradient used for the semi-preparative HPLC on sub-fraction E14035 A2J 
 
Extract Fraction Weight (mg) 
E14035 
A2J1 1,18 
A2J2 0,57 
A2J3  -  
A2J4 0,22 
A2J5 0,09 
A2J6 0,34 
A2J7 0,03 
A2J8 0,62 
A2J9 0,09 
A2J10 0,44 
A2J11 0,29 
A2J12 0,59 
A2J13 3,57 
Table 13: Weight of sub-fractions of E14035 A2J after HPLC. No weight was obtained for subfraction A2J3. 
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4. Results 
4.1 Assay optimization 
For the first months, the main goal was to setup the assay conditions and to optimize the 
process of inflammation, induced by LPS. Different concentrations of LPS were tested 
(100 ng/mL, 50 ng/mL and 25 ng/mL) and different designs were tested: 96 well-
microplate vs 24-well microplate. The Figure 24 shows one example of the assay in a 96-
well microplate that did not work perfectly, since LPS-stimulation did not work well. In 
several trials, we could not induce NO production in the 96-well format, but only in the 24-
well format. Consequently, we used the 24-well format for all following assays. The 
induction of inflammation had to be improved through several assays, since in the 
beginning no consistent results were obtained. Finally, we increased the concentration to 
1000 ng/mL LPS, which demonstrated consistent results and a stable induction of 
inflammation. Consequently, this concentration was selected for the bioassays with the 
extracts/fractions from cyanobacteria. 
Figure 24: LPS assay performed with 1 μg/ml concentration of LPS in 96 well-microplate. In LPS assay 1 the LPS 
was pipetted directly into the medium, while in the assay 2 the LPS was first mixed with the medium and vortexed. 
(Final concentration: LPS1: 0.0099 μg/mL; LPS5: 0.048 μg/mL) 
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Figure 25: Example of a successful LPS assay in a 24-well microplate with different concentrations of LPS inducing 
the inflammation in the cells (LPS 100: 100 ng/ml; LPS 50: 50 ng/ml; LPS 25: 25 ng/ml). The graphic shows the % of 
NO production in the culture supernatant measured by the Griess Reaction at 540 nm. 
 
4.2 Screening assays for cyanobacterial activity 
The extracts used during the present work were obtained in a previous project 
(MarBiotech), following the standard procedure of the BBE group in CIIMAR. 
Cyanobacterial biomass was submitted to a normal phase vacuum liquid chromatography 
which resulted in 9 - 11 fractions. 
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Figure 26: Representation of the results relative to the strain LEGE 07211, LEGE 07212, LEGE 00237 and LEGE 
XX280 and respective fractions A-I in NO units, after 24 h of exposure. CTR: 0.3 % of DMSO, LPS: 1 µg/ml.  
Fractions were co-exposed to the same LPS concentration. Two replicate wells were assayed for each group. 
 
In our assay, we used at least 2 replicate wells for each treatment, which allowed us to 
have a maximum of 12 different groups in a 24-well plate. The assay design included 2 
replicate wells for the solvent control (0.3% of DMSO), for LPS (1 µg/ml) with 0.3% of 
DMSO, and for each fraction.  
The activity of each fraction of the strain LEGE 07211 is shown in NO units. Regarding to 
this, fraction E14031B revealed more anti-inflammatory activity. This extract was able to 
reduce the induction of inflammation by LPS, from 1 µM to 0.7 µM (1.4 fold), a similar level 
as the solvent control (0.6 µM). The strain LEGE 07212 had one fraction that showed 
strong potential in anti-inflammatory activity – E14067A, which inhibited the LPS induced 
NO production (0.9 µM) to the similar level as the solvent controls cells in this assay (0.6 
µM). The other fractions did not reduce the LPS-induced NO production, but increase the 
inflammatory process (Figure 26). LEGE 00237 showed strong anti-inflammatory 
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potential, since one fraction (E14032A) decreased effectively the LPS-induced NO 
production. The reduction of NO production was about 5fold less compared to the LPS 
treatment (LPS 5 µM, E14032A 1 µM). The fractions of strain LEGE XX280 did not show 
any anti-inflammatory activities. 
Most of the fractions of the strains LEGE 06079, LEGE 91094, LEGE 06071 and LEGE 
07084 did not show significantly results regarding to anti-inflammatory activity (Figure 27). 
Figure 27: Representation of the results relative to the strain LEGE 06079, LEGE 91094, LEGE 06071 and LEGE 
07084 and respective fractions A-I in NO units, after 24 h of exposure. CTR: 0.3 % of DMSO, LPS: 1 µg/ml.  
Fractions were co-exposed to the same LPS concentration. Two replicate wells were assayed for each group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Representation of the results relative to the strain LEGE 06077 and respective fractions A-J in NO units, 
after 24 h of exposure. CTR: 0.3 % of DMSO, LPS: 1 µg/ml.  Fractions were co-exposed to the same LPS 
concentration. Two replicate wells were assayed for each group. 
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The analysis of the fractions from the strain LEGE 06077 - E13013 showed that fraction E 
had a pro-inflammatory activity, with a NO production of 1.5 µM, compared to a NO 
production of 1 µM, on the LPS treatment (Figure 28). 
The analysis of the fractions from LEGE 06363 from the cyanobacteria collection revealed 
strong anti-inflammatory activity for fractions A, C and G, while pro-inflammatory activity 
was observed in fraction D. 
Figure 29: Representation of the results relative to the strain LEGE 06363 and respective fractions in NO units, after 
24 h of exposure. CTR: 0.3 % of DMSO, LPS: 1 µg/ml.  Fractions were co-exposed to the same LPS concentration. 
Two replicate wells were assayed for each group. The right panel shows the results for the sub-fractions of fraction 
E14026A. 
 
After the column chromatography of the fraction LEGE 06363 A, the obtained sub-
fractions were re-tested. The sub-fraction A7 showed strongest anti-inflammatory activity 
(Figure 29). The subsequent NMR analysis demonstrated that the sub-fraction A7 still 
contained some complexity and would need further purification steps to isolate the 
responsible compound (Figure 30). However, due to the relatively low biomass of 1 mg, it 
was decided to continue the bioassay-guided isolation of novel compounds with another 
fraction that showed promising anti-inflammatory activity, but had a higher biomass 
available. More biomass will be needed in the future, in order to isolate the responsible 
compound.  
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Figure 30: 1H NMR of the fraction E 14026 A7 
 
The fraction A from the cyanobacterial strain LEGE 03283 showed strong anti-
inflammatory activity (Figure 31). After flash chromatography of this fraction with an initial 
weight of 173.8 mg, the obtained sub-fractions were re-tested. Clearly, the sub-fraction A2 
(E14035 A2) displayed the strongest anti-inflammatory activity. Following, the sub-fraction 
E14035 A2 with 20.66 mg was submitted to further purification by HPLC, as explained in 
the material and methods part.  
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Figure 31: Representation of the results relative to the strain LEGE 03283 and respective fractions in NO units, after 
24 h of exposure. CTR: 0.3 % of DMSO, LPS: 1 µg/ml.  Fractions were co-exposed to the same LPS concentration. 
Two replicate wells were assayed for each group. The panels show the results for activity screening of the sub-
fractions. 
 
Figure 32: Chromatogram of E14035 A2 showing highlighted sub-fractions that were collected. Conditions of 
the injection were 500 μL at a concentration of approximately 4.5 mg mL-1. 
 
The fractions A2C, A2H, A2J, and A2K from the cyanobacterial strain LEGE 03283 were 
the most active ones in the biological assays using the Griess method. In the 1H NMR 
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spectrum, the sub-fraction A2J contained just a few compounds, and further purification 
were necessary.  
 
 
 
 
 
 
 
 
 
 
Figure 33: 1H NMR of the fraction E 14035 A2 J 
 
Figure 34: Chromatogram of E14035 A2J showing highlighted sub-fractions that were collected. Conditions of 
the injection were 100 μL at a concentration of approximately 4.5 mg mL-1. The detection was made at 275 nm 
and 254 nm. 
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The HPLC separation of the sample E14035 A2J was performed subsequently with 100 
µL loaded each time. Each run had a period of time of 70 minutes and it was necessary to 
perform about 20 runs to separate the whole sample. The signal detection of different 
compounds was better at 275 nm wavelength compared to 254 nm wavelength.  
After HPLC purification, 13 fractions were obtained and tested for anti-inflammatory 
activity. Fractions A2J7, A2J8, A2J9, A2J10, A2J11 and A2J12 revealed to be the most 
active ones (Figure 31). A2J7, A2J9, A2J10, A2J11 and A2J12 were subjected to a 1H 
NMR analysis to check their complexity (Figure 35).t 
These subfractions contain still two or more compounds, therefore further purification by 
HPLC will be necessary.  
Figure 35: 1H NMR of the fraction E 14035 A2J7 (on the bottom), A2J9, A2J10, A2J11 and A2J12 (on the top) 
(recorded at 600 mHz). 
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Strain Fraction Anti-inflammatory activity 
LEGE 07211 E14031 B ++ 
LEGE 00237 E14032 A ++ 
LEGE 06363 E14026 A7 ++ 
LEGE 03283 E14035 A2J ++ 
Table 14: Summary of anti-inflammatory activity from all tested cyanobacterial strains 
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5. Discussion 
As explained previously in this work, inflammation is a process that happens as a 
response of the immune system of mammals to protect them against infections derived 
from bacterial or fungi (Kumar et.al., 2015; Cruvinel et.al., 2010). Be a chronic disease or 
an acute disorder, or even a light migraine, humans easily resort to synthetic drugs to 
treat the symptoms. The most used are NSAID’s and act as a blockade of the mediators 
that are produced during the process of inflammation. (www.CRBestBuyDrugs.org, Rao & 
Knaus, 2008). Although the treatment of inflammation by NSAID’s is effective, the 
constant use of these drugs can still bring many side effects such as the injury of the 
gastrointestinal and renal systems, fluid and salts retention, heart attacks, strokes, and 
others (Qandil et.al., 2012; Gouda et.al., 2013; Rao & Kaus, 2008). Because NSAID’s can 
manifest adverse side effects (Fitzgerald, 2004), one effort has been to identify natural 
products, derivate from plants, microalgae and cyanobacteria for the prevention and 
treatment of inflammatory disorders. 
 
LPS optimization 
 
Before all the bioassays with the cyanobacterial extracts, we had to optimize the method 
of induction of inflammation in the cells. We used LPS, the major component of the gram 
negative bacteria, which induces inflammation and therefore stimulate the NO production 
by macrophages. We tested different concentrations and different ways of performing the 
assay. Most of the works previously published in this matter, indicated that the best 
concentration is 1 µg/ml to induce inflammation and NO production in RAW 264.7 cells 
(Aldrige et.al., 2008; Damte et.al., 2011; Dey et.al., 2005, Kellog et.al., 2015; Yang et.al., 
2014; Yang et.al., 2012). In BV2 microglia, the inflammatory response required a lower 
LPS’ concentration and 100 ng/ml was frequently used (Henn et.al., 2009). Olszanecki 
et.al. (2006) showed that LPS at 1 µg/ml caused a significant increase of NO 
accumulation, after 24 hours of incubation, in the macrophage cell line J744.2. The human 
cell line – Thp1 – has to be treated with 10 µg/ml of LPS to induce inflammation 
(Speranza, 2010). 
In our assays, the best concentration was 1 µg/ml that consistently increased the NO 
production. The best conditions were to mix the LPS rigorous with the medium and to add 
directly to the microplate. If we added the LPS to the medium in the plates, sometimes the 
assay did not work well. We also tried to induce NO production by LPS in 96 well-
microplates, however without success. In contrast, other works with RAW 264.7 cells 
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demonstrated that assays were performed in 96 well-microplate with good and expected 
results (Damte et.al., 2011; Villa et.al., 2010 (b); Yang et.al., 2014). The reasons for this 
discrepancy are not clear yet. One part of the explanation could be that LPS is an apolar 
molecule; the dissolution of LPS is not easy, and additionally 96 well-microplate has more 
plastic area in direct contact with LPS. We suppose that the LPS may interact with the 
plastic of the microplate, which will reduce its concentration in the medium. However, 
inflammation assays in 24 well-microplate were more common in this cell line that in 96 
well-microplate (Dey et.al., 2005; Jo et.al., 2010; Kellog et.al., 2015; Oliveira et.al., 2014; 
Yang et.al., 2012).  
 
Cyanobacterial strains with anti-inflammatory activity 
 
In this work, we tested 117 fractions from 13 marine cyanobacteria strains of different 
classes for their anti-inflammatory activity. The chosen strains have already shown 
previous activity in other studies like in an adipocytes cell line. Fractions of Planktothrix 
planctonica LEGE XX280 (E14028 I) and Aphanizomenon sp. LEGE 03283 (E14035 B) 
exerted strong positive effects in proliferative and metabolic activity of 3T3-L1 pre-
adipocytes. Fractions from Synechocystis sp. LEGE 07211 (E14031 D) and from 
Oscillatoria limnetica LEGE 00237 (E14032 H and J) showed remarkable activity in the 
modulation of adipogenesis of murine pre-adipocytes (Castro, 2016). It should be 
generally noted that different fractions of the same strains had anti-inflammatory activities 
or anti-obesity activities.  
However, in some cases a concordance was observed, meaning that fractions had both, 
anti-inflammatory and anti-obesity activities. From Synechocystis sp. LEGE 07211, we 
obtained 9 fractions, and E14031 B reduced the LPS-induced NO production. The same 
fraction strongly inhibited adipogenesis in 3T3-L1 cells in a previous study (Castro, 2016) 
and now has a strong potential in anti-inflammatory activity. 
 
The E14067 A from Limnothrix sp. LEGE 07212 revealed anti-inflammatory activity, 
reducing NO production about 25%. C-phycocyanin is a blue photosynthetic accessory 
pigment that was firstly isolated from Spirulina, accounting for 14% of the cyanobacteria’s 
dry weight. C-phycocyanin exerted strong anti-inflammatory effects in Kupffer cells from 
mice liver through the inhibition of TNF-α response after induction of thyroid calorigenesis, 
and was able to reduce colonic injury and inflammatory cell infiltration in rats with acetic 
acid induced colitis (Castro et.al., 2016). Other studies revealed that phycocyanin is a 
powerful antioxidant agent (Gantar et.al., 2012) and that some other cyanobacterial 
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genera can be a source of this compound. In this study, the authors isolated the bioactive 
compound from the strain Limnotrhrix sp. 37-2-1 and then evaluate its antioxidative 
activity by electron spin resonance (ESR) spectroscopy, which showed 100% activity at 
0.15 mg/ml (Gantar et.al., 2012). We can hypothesize that C-phycocyanin is the 
compound present in the tested strain Limnothrix sp. LEGE 07212 and it is interacting with 
some pathway involved in the inflammatory response, explaining, thus, the fact that its 
fraction has anti-inflammatory activity. 
 
Researchers have pointed to more complex bacteria (from orders Oscillatoriales, 
Nostocales or Stigonematales) as more prolific in secondary metabolites. However, our 
bioassays show that simpler cyanobacteria, like Synechocystis sp. LEGE07211 from the 
sub-class Chroccocales, may also possess novel secondary metabolites with 
pharmaceutical and biotechnological potential. 
 
The strain Oscillatoria limnetica LEGE 00237 showed strong evidence in having anti-
inflammatory activity for the fraction E14032 A with a reduction of the NO production from 
4.82 ± 0.015 µM in the LPS’ treatment to 1.08 ± 0.14 µM (5 fold less than in the LPS 
treatment). Although this strain and fraction in particularly exerted strong effects on the 
RAW 264.7 cell line, we could not evaluate its bioactive potential, because of the low 
available biomass – 36.5 mg – that was not enough to proceed with the purification and 
isolation of the responsible compound.  
 
The strain Phormidium sp.  LEGE 06363 with the extract E14026 from the cyanobacteria 
collection revealed some bioactive fractions: A, C and G with anti-inflammatory activity 
and one (E14026 D) with pro-inflammatory activity (Figure 36). Ulivi et.al. (2011) already 
revealed that an isolated compound – monogalactosyldiacylglycerol (MGDG) - of the 
cyanobacterial strain Phormidium sp. repressed the inflammatory response induced in 
human articular cells via IL-1α + TNF-α without impairment of cell viability. In this case, 
the main target of MGDG were the IL-6 and its soluble receptor, since they are related in 
inflammatory and degenerative diseases. Increased levels of IL-6 and sIL-6R were found 
in synovial fluids and sera from osteoarthritis and rheumatoid arthritis patients and their 
level correlates with the increased leukocyte infiltration in synovial tissue. In in vitro 
assays, this compound exerted strong anti-inflammatory activity in cultured articular 
chondrocytes through the p38 and NF-KB pathways inhibition. In addition, MGDG could 
be able to activate an anti-inflammatory pathway involving 15ΔPGJ2. Another strain of this 
class and order Nostocales – Phormidium tenue – produced several diacylglycerols that 
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inhibited chemically induced tumours on mice and was reported as HIV inhibitor (Singh 
et.al., 2005). 
Regarding to our results, it was decided primarily to perform a column chromatography by 
gravity to separate the compounds present in the mixture of the E14026 A with a weight of 
about 69.5 mg. This fraction was the most non-polar, and through the gradient of solvents 
used for this chromatography 8 sub-fractions were obtained. Of this 8 sub-fractions, one 
reveal to be the most active one in the biological assays – E14026 A7. For this fraction, 
we performed the 1H NMR analysis and as demonstrated in the results, the fraction is not 
isolated and it is still constituted by several different compounds. NMR is used as a 
screening technique in several research projects, for both comparison of spectral data 
found in literature or between fractions. Nuclear magnetic resonance has been a widely 
used method, extremely important, aiding the bioactivity guided fractionation process and 
structure elucidation of new metabolites (Pellecchia et.al., 2002; Oldoni et.al., 2016). 
Throughout this work, we used 1H NMR to evaluate the separation procedure, since 
different NMR spectra are obtained for each fraction. Once the compounds are pure, 1D 
and 2D NMR can be used to elucidate the structure of the compounds.  
Due to the low amount of biomass in the sub-fraction E14026 A7 (0.96 mg), it was not 
possible to carry on the isolation and purification of the compound with anti-inflammatory 
activity. Considering this result, it would be interesting to initiate a new cyanobacteria 
culture to grow the strain LEGE 06363 in a large scale in order to continue the sub-
fractionation of the E14026 A7 and to isolate the compound in the future.  
 
The fraction E14035 A from Aphanizomenon sp. LEGE 03283 from the order Nostocales 
revealed strong anti-inflammatory activity. E14035 A inhibited the 44% of the NO 
production, from 1.33 ± 0.038 µM (in the LPS treatment alone) to 0.79 ± 0.003 µM. This 
strain already showed bioactivity (E14035 B) in other assays, and demonstrated strong 
effects in proliferative and metabolic activity of 3T3-L1 pre-adipocytes (Castro, 2016). The 
strain Aphanizomenon flos-aquae is a type of cyanobacteria that are known to produce 
natural products rich in essential amino acids, c-linolenic acid (GLA), fibers, B vitamins, 
calcium, phosphorous, iron, pigments such as b-carotene, chlorophyll, xanthophylls, and 
others (Ku et.al., 2013). Aphanizomenon flos-aquae is also known to produce several 
cyanotoxins that can be harmful to human and animals (Preuβel et.al., 2006, Papendorf 
et.al., 1997), and it was reported that this strain is capable of producing antibiotics (Falch 
et.al., 1995, Østensvik et.al., 1998). 
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The extract E14035 A from LEGE 03283 was subjected to a SPE. This method was not 
perfect, and did not have a 100% of recovering of the biomass, because there was some 
disturbations in the solid phase. Probably, the silica was not well stabilized, thus in a 
certain moment of the chromatography, some compounds were not perfectly separated. 
The biological assays were performed again, and the fraction E14035 A2 showed to be 
the most active one with an inhibition of about 54% in NO production. According to the 
NMR analysis, sub-fraction E14035 A2 had some complexity with several compounds in 
its mixture. Following, HPLC allowed the separation of the fraction A2 (20.66 mg) into 11 
new sub-fractions. From these 11 sub-fractions (A2A-A2K), three revealed anti-
inflammatory activity. Through NMR analysis, it was possible to check the quantity of 
compounds still present in each sub-fraction and the complexity of each one. Once more, 
the NMR’ spectrum showed that this compound was not pure yet and further purification 
was needed to isolate the bioactive compound. One bioactive sub-fraction – A2 J – had 8 
mg after HPLC, and its NMR spectrum revealed that we still have a mixture of three or 
more compounds. This spectrum showed some instabilities, probably because the used 
vials were not completely dried and some solvents could have interacted with the 1H NMR 
detection and behaved like a “mask”. A2 J, in this case, was chosen to be submitted to a 
new separation by HPLC, in which we obtained 13 sub-fractions (A2J1-A2J13). From 
these 13 sub-fractions, five of them revealed anti-inflammatory activity – A2J7, A2J9, 
A2J10, A2J11 and A2J12. 
In another study, a dichloromethane extract of A. auricula-judae inhibited LPS-induced NO 
production (1 µg/ml) in a dose-dependent manner in the concentration of ≥ 10 μg/ml (p < 
0.05). The higher dose of A. auricula-judae extract (100 µg/ml) allowed a 4fold decrease 
of the NO production from about 16 µM (in the LPS treatment alone) to about 4 µM 
(Damte et.al., 2011). In comparison, the fractions E14035 A2J9 and E14035 A2J12 
showed a 2fold inhibition of NO production from 0.993 ± 0.012 µM to 0.572 ± 0.0019 µM 
and 0.572 ± 0.0012 µM, respectively. It seems that our subfractions had a lower strength 
of inhibition; however, the comparison is difficult, since the observed inhibition from our 
subfractions was nearly 100%, reaching the same level as the solvent control. Higher 
sensitivity could only be shown by increasing the induction of NO production by LPS or by 
testing the pure, responsible compound of the mixture from the subfraction. 
By the interpretation of the NMR’ spectra of these fractions, we can infer that they are not 
pure compounds yet; it seems that some of the compounds are present in all these 
fractions, which could be analogues. More analyses have to be done to conclude, which 
compounds are present in the bioactive fractions. Another round of purification has to be 
done to isolate the compound, however the final weight that we have to perform this is not 
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compatible with the purification process. Therefore, it requires a new period to allow the 
growth of this strain, and after the isolation of the compound, 1D and 2D NMR can be 
used to perform the elucidation of the chemical structure. LC/MS of these subfractions will 
be performed in the near future.  
Once a cyanobacterial compound is isolated and characterized, future studies will focus 
on the mechanistic pathway through which these compounds are able to exert their 
effects. 
Comparing the levels of inhibition of NO production with previous studies that used the 
same methodology in RAW 264.7 cells (Yang et.al., 2012), we can conclude that these 
last sub-fractions have some potentiality for anti-inflammatory compounds. As Yang et.al. 
(2012) showed before, 6,6′-bieckol – a compound isolated from a brown alga (Ecklonia 
cava) – significantly inhibited LPS-stimulated NO and PGE2 production when treated with 
100 and 200 μM in RAW 264.7 cells. This compound decreased, at these concentrations, 
the NO production from 50 µM to less than 20 µM, what proves that 6,6′-bieckol has anti-
inflammatory activity. Comparing to the LPS induction treatment, the fractions with anti-
inflammatory activity (A2J7, A2J9, A2J10 and A2J13) inhibited almost 50% the NO 
production to the same level of the solvent control. For that reason, we can suppose that it 
leads to an absence of inflammation in macrophage cell line. 
Previous studies suggested that eicosapentaenoic acid (EPA), an Omega 3 Fatty Acid (ω-
3 FA) was able to inhibit the NO production. The decrease in NO production occurred at 
the level of iNOS protein expression shown by western blot. The treatment with LPS at 1 
µg/ml in RAW 264.7 cells revealed a NO production of 29.31 ± 0.57 μM after 24 hours, 
and this effect was reduced by pre-treatment with 1.44 μl.ml-1of ω-3 FA (Corresponding to 
a concentration of 100 μM of EPA) to a 3.00 ± 0.99 μM NO (Aldrige et.al., 2008). 
As referred before, flavonoids and alkaloids have anti-inflammatory activity, so they could 
be constituents of the bioactive compounds in our case. 
C-phycocyanin (C-PC), as already mentioned before, is a major component with 
interesting bioactivities from cyanobacteria. C-PC’s that come from different species of 
cyanobacteria, such as Aphanizomenon sp., Spirulina sp., Phormidium sp., Lyngbya sp., 
Synechocystis sp., Synechococcus sp. have already been isolated and investigated. C-
PC is an anti-inflammatory protein, since it inhibited NO production and iNOS expression 
in RAW 264.7 cells, probably due to the suppression of TNF-α synthesis and nuclear NF-
kB activation (Rahman, 2008).  
More investigation and efforts should be applied in the future in the case of the strain 
LEGE 03283. It would be essential to perform a large scale production of biomass from 
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this strain in order to isolate the bioactive compound, to determine the IC50 and to assess 
the cytotoxicity of the compound. Furthermore, other techniques could be applied to 
characterize its inflammation potential, such as, analysis of mechanisms in vitro that have 
different targets as the cytokines TNF-α or IL-6. Villa et.al. (2010 (b)) used in their 
research ELISA and quantitative real-time Polymerase Chain Reaction (qRT-PCR) to 
analyze cytokines and enzymes involved in the inflammation process. Some inflammation 
reliefs are known to inhibit the COX enzymes (Koeberle & Werz, 2014). Strategies to 
evaluate these enzymes and cytokines involved in the inflammation process would be an 
interesting way to continue the work of cyanobacterial compounds with anti-inflammatory 
activities. Also, it needs to be evaluated if the compound in study has multiple 
mechanisms of action or just one. 
Moreover, we could perform a study in vivo, for example. After the isolation of the 
compound with strong anti-inflammatory potential, it should be tested in a more complex 
model system, like Wistar rats. Alolga et.al. (2015) used Wistar rats in a previous study to 
evaluate the ability of Kang 601 heji (K-601), an ordinary Chinese herb used to treat cold 
and fever, to inhibit the inflammation process. For future works, we could use the same 
endpoints as in this previous investigation, in order to better understand the composition 
and the mechanisms of action behind the cyanobacteria Aphanzomenon sp. LEGE 03283.  
Kang 601 heji (K-601) is a traditional Chinese preparation with therapeutically effects used 
for common cold comprising five herbs, Lonicera japonica Thunb. (L. japonica), Isatis 
indigotica Fort. (I. indigotica), Rheum palmatum L., Phellodendron chinense Schneid. (P. 
chinense), and Scutellaria baicalensis Georgi (S. baicalensis). Chromatography analysis 
and mass spectra were executed to discover the constituents of the formulation K-601, 
and the results revealed it contains several compounds ranging from flavonoids, alkaloids, 
isoflavonoids, etc. The full outcome revealed 50 identified compounds. In the assays 
performed in this work, K-601 possesses the ability to reduce fever in a dose-dependent 
manner. The compound studied revealed an ability to reduce NO production, as 
measured by the Griess’ method; however, the results in “NO concentration” were not 
available on the published paper. The possible mechanisms of actions of this formulation 
could be the inhibition of NO production by the cells, reduction of release of cytokines and 
the inhibition of PGE2 release during inflammation. Flavonoids, that are included in its 
formulation, have been found to have anti-oxidative and free radical scavenging activities. 
These compounds are able to control some cellular processes of inflammation related 
cells, as, mast cells, macrophages, lymphocytes and neutrophils. Some of them modulate 
the enzyme activities of arachidonic acid, metabolizing enzymes such as cyclooxygenase, 
lipoxygenase, phospholipase A2, NO synthase. In that way, the inhibition of these 
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enzymes leads to a decrease in arachidonic acid, leukotrienes, prostaglandins and NO, 
which are crucial mediators of the inflammation process. The anti-inflammatory ability of 
flavonoids could be related to the inhibition of the nuclear factor kappa B transcription 
activation (Alolga et.al., 2015). The alkaloids constituents have demonstrated to be strong 
anti-inflammatory agents, as for example, the alkaloidal fraction from Alstonia scholaris 
including picrinine, vallesamine and scholaricine that showed strong anti-inflammatory 
activity. The IC50 values suggested that compounds 5–14, all indole aglycones, exhibited 
potent inhibitory activities against NO production, with IC50 values of 5.34 to 13.45 μM (the 
positive control, indomethacin, had an IC50 value of 14.10 μM). These results cannot be 
directly compared with ours since have a mixture of various compounds and do not have 
the chemical structure of the responsible compounds. However, the chosen concentration 
of 30 µg/ml in our screening assays reveals that we have observed relevant anti-
inflammatory activities in the cyanobacterial fractions. In comparison, the IC50 
concentration of the model compound indomethacin (14 µM) corresponds to 
approximately 5 µg/ml, but is already a solution of a pure and single compound.  
 
Bioactivity guided-fractionation vs other methodologies  
 
Bioactivity guided-fractionation is a common method used to discover novel natural 
compounds that focusses on extract preparation, fractionation, biological screening with 
appropriate assays and further, the process of isolation, purification and structural 
elucidation of the active compounds (Oldoni et.al., 2016; Bargougui et.al., 2014; Ding 
et.al., 2013). This technique has been very helpful for the discovery of compounds for 
specific targets, and generally appeals to chromatographic techniques as liquid 
chromatography, HPLC, liquid-liquid or solid phase extraction (Oldoni et.al., 2016). 
However, bioactivity guided fractionation has the disadvantage of being time consuming 
and expensive, since high volumes of organic solvents are used, and sometimes these 
solvents are hardly compatible with bio- or biochemical assays (Cutignano et.al., 2015; 
Weller, 2014). Moreover, this process has the disadvantage of the possibility to elucidate 
already described compounds from the literature (Katiyar et.al., 2012). Synergisms and 
antagonisms between compounds can occur that can ultimately result in the loss of 
activity or the blocking of the activity of a compound, respectively (Koeberle & Werz, 
2014). Another limitation is that the method is resource consuming. Each fractionation that 
is executed for a compound requires a preparation of new exposure solutions, which 
results in losses of biomass of the sub-fractions (Yuliana et.al., 2013). If the bioassay fails, 
additional biomass is needed to prepare new solutions and to re-test, as happened in 
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some of the fractions in this present work. However, this approach ensures that a 
compound with a specific biological activity is identified. Some investigations followed this 
methodology with interesting outcomes, as the case of the discovery of proanthocyanidins 
with anti-oxidant activity (Oldoni et.al., 2016), polyphenols with anti-tumor activity from the 
extract of Rhus verniciflua (Kim et.al., 2013), hierridin B, extracted from the marine 
picocyanobacterium Cyanobium sp. LEGE 06113 with anti-tumor activity (Leão 
et.al.,2013), or lignans from the root of Machilus obovatifolia (Lin et.al., 2015), between 
others. 
In contrast, different approaches exist for the isolation of novel secondary metabolites. 
Basically, these approaches make the opposite of the previous one. It is based on the 
identification and elucidation of the structure of new compounds, before the activity will be 
analyzed in bioactivity assays. Isolated compounds with chemical identities of interest are 
screened for specific bioactivities, a process that contrasts with the classic bioactivity 
guided-fractionation. This methodology allowed the discovery and isolation of a variety of 
bioactive compounds, such as the xanthones from the species Garcinia succifolia 
(Duangsrisai et.al., 2014). The disadvantage of this approach is that sometimes novel 
compounds are described that does not have any relevant bioactivity.  
The process of dereplication technique is often used in an early stage of the work, before 
the isolation and characterization of compounds in order to discriminate already 
characterized compounds. The crude extract is analyzed by spectroscopy and 
supplementary analyses are done just for the compounds with non-characterized features, 
which allow a higher probability to elucidate and identify novel secondary metabolites. The 
most common methodologies are UV spectroscopy and mass spectrometry combined 
with HPLC (LC-UV/PDA, LC-MS) that allow the identification of certain structural classes 
and gives leads on the molecular weight and formula (Hubert et.al., 2014).  
However, they often lack in flexibility and a previous method development is needed, 
which consumes time and money. Therefore, from this point of view, a bioactivity guided 
fractionation is a more versatile technique. In our lab, this approach allows to find novel 
secondary metabolites with a larger range of bioactivities and to explore the 
cyanobacterial biotechnological and pharmaceutical potential. 
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6. Conclusion 
Through the years, it is recognized that pathologies associated with inflammation are a 
huge health problem. People rely on medicines to control the pain associated to the 
inflammation processes, which have several side effects, like NSAID’s. This work aimed 
to identify a novel compound with anti-inflammatory activity from a natural resource, 
preferably with less adverse effects. Cyanobacteria are known for the ability to produce 
bioactive compounds, some with potential application in this area. This is particular true 
for marine cyanobacteria, since freshwater cyanobacteria species such as 
Aphanizomenon flos-aquae, Spirulina platensis, Spirulina maxima and Nostoc commune 
have been used for feed and cosmetics (Raja et.al., 2016). Although different bioactivities 
of cyanobacteria are reported, especially in what concerns to human health and well-
being, just few information are available on the potential uses of these organisms for anti-
inflammatory treatment. 117 fractions from 13 cyanobacterial strains derived from the 
cyanobacterial culture collection of CIIMAR (BEE group) were screened for their first time 
for their anti-inflammatory potential.  
A fraction from Synechocystis sp. LEGE07211 (E14031D), a more simple cyanobacteria 
belonging to the Chroccocales genus, showed strong anti-inflammatory activity in RAW 
264.7 cell line. These results confirm that unicellular free-living species of cyanobacteria 
are prolific in secondary metabolites with bioactivity of interest.   
The strain Phormidium sp.  LEGE 06363 with the sub-fraction E14026 A7 revealed strong 
potential for anti-inflammatory activity; however it was not possible to isolate the 
responsible compound, since the available biomass was not sufficient for a complete 
isolation.  
The fractions E14035 A2J9 and E14035 A2J12 from Aphanizomenon sp. LEGE 03283 
from the order Nostocales revealed strong anti-inflammatory activities. Again, the biomass 
of the sub-fractions was not sufficient to complete the isolation procedure, and final NMR 
spectra indicated the presence of more than one compound.  
Even though this research supplies data about the potential properties of the strains, 
further research efforts must be conducted. Further biomass productions have to be done 
in the future to provide the raw material for successful isolations. Obtained results can be 
used to start with efficient chromatographic procedures to isolate and purify the 
responsible compounds of the anti-inflammatory activity. A new and different methodology 
should be applied to assess the anti-inflammatory activity in order to complement the data 
developed in this work. For example, zebrafish embryos offer a fast and sensitive 
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methodology to screen for anti-inflammatory activities, which delivers on the same time 
information about potential toxic side effects in vivo.  
To the best of our knowledge, this is the first work focusing on bioactivity guided isolation 
of novel cyanobacterial secondary metabolites for anti-inflammatory pathologies or 
diseases using the cyanobacterial culture collection of CIIMAR.  
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Appendixes  
Appendix A - 1H NMR data for sub-fractions resulting from E14035A2 successive 
fractionings. 
 
Figure 1 – 1H NMR spectral data for E14035A2A in CDCL3 (recorded at 400 MHz). 
Figure 2 – 1H NMR spectral data for E14035A2B in CDCL3 (recorded at 400 MHz). 
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Figure 3 – 1H NMR spectral data for E14035A2C in CDCL3 (recorded at 400 MHz). 
 
 
 
Figure 4 – 1H NMR spectral data for E14035A2D in CDCL3 (recorded at 400 MHz). 
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Figure 5 – 1H NMR spectral data for E14035A2E in CDCL3 (recorded at 400 MHz). 
 
 
Figure 6 – 1H NMR spectral data for E14035A2F in CDCL3 (recorded at 400 MHz). 
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Figure 7 – 1H NMR spectral data for E14035A2G in CDCL3 (recorded at 400 MHz). 
 
Figure 8 – 1H NMR spectral data for E14035A2H in CDCL3 (recorded at 400 MHz). 
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Figure 9 – 1H NMR spectral data for E14035A2I in CDCL3 (recorded at 400 MHz). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – 1H NMR spectral data for E14035A2J in CDCL3 (recorded at 400 MHz). 
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Figure 11 – 1H NMR spectral data for E14035A2K in CDCL3 (recorded at 400 MHz). 
 
